nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04508075,NA,2020-08-07,NA,NA,2021-09-06,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"January 9, 2021",Actual,2021-01-09,NA,Interventional,COVID-19,NA,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:42Z,2021-10-12T06:58:42Z,119
NCT04497298,NA,2020-07-31,NA,NA,2021-07-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVID-19-101,NA,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:09Z,2021-10-12T07:00:09Z,181
NCT04495933,NA,2020-07-13,NA,NA,2021-08-23,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 13, 2020",Actual,2020-07-13,August 2021,2021-08-31,"February 2, 2022",Anticipated,2022-02-02,"November 6, 2021",Anticipated,2021-11-06,NA,Interventional,NA,NA,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over","Active, not recruiting",NA,Phase 1,216,Actual,The University of Queensland,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2021-10-12T07:00:22Z,2021-10-12T07:00:22Z,133
NCT04480957,NA,2020-07-17,NA,NA,2021-08-12,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"August 4, 2020",Actual,2020-08-04,August 2021,2021-08-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,NA,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:16Z,2021-10-12T07:02:16Z,144
NCT04471519,NA,2020-07-11,NA,NA,2021-05-18,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"July 15, 2020",Actual,2020-07-15,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"July 31, 2020",Actual,2020-07-31,NA,Interventional,BBV152,NA,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,755,Actual,Bharat Biotech International Limited,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:25Z,2021-10-12T07:03:25Z,230
NCT04463472,NA,2020-07-08,NA,NA,2021-08-17,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z,139
NCT04475302,NA,2020-07-16,NA,NA,2021-09-17,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"July 1, 2020",Actual,2020-07-01,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,"Active, not recruiting",NA,Phase 3,2175,Actual,"Tuberculosis Research Centre, India",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:57Z,2021-10-12T07:02:57Z,108
NCT04473690,NA,2020-07-14,NA,NA,2021-10-05,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"December 30, 2020",Actual,2020-12-30,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85","Active, not recruiting",NA,Phase 1/Phase 2,101,Actual,"Kentucky BioProcessing, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Plan is to share study data by dosing group in publications,2021-10-12T07:03:09Z,2021-10-12T07:03:09Z,90
NCT04470609,NA,2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:33Z,2021-10-12T07:03:33Z,539
NCT04466085,NA,2020-07-08,NA,NA,2020-12-01,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"July 12, 2020",Actual,2020-07-12,December 2020,2020-12-31,"December 15, 2021",Anticipated,2021-12-15,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years","Active, not recruiting",NA,Phase 2,900,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z,398
NCT04461379,NA,2020-07-02,NA,NA,2020-11-12,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,NA,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z,417
NCT04456595,NA,2020-06-30,NA,NA,2021-02-10,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"July 21, 2020",Actual,2020-07-21,February 2021,2021-02-28,February 2022,Anticipated,2022-02-28,"December 17, 2020",Actual,2020-12-17,NA,Interventional,PROFISCOV,NA,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac","Active, not recruiting",NA,Phase 3,12688,Actual,Butantan Institute,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:22Z,2021-10-12T07:05:22Z,327
NCT04453852,NA,2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,NA,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:43Z,2021-10-12T07:05:43Z,243
NCT04447781,NA,2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2021-10-12T07:06:32Z,2021-10-12T07:06:32Z,503
NCT04450004,NA,2020-06-18,NA,NA,2020-10-21,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 10, 2020",Actual,2020-07-10,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:16Z,2021-10-12T07:06:16Z,439
NCT04445194,NA,2020-06-16,NA,NA,2020-12-01,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"September 20, 2021",Anticipated,2021-09-20,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:55Z,2021-10-12T07:06:55Z,398
NCT04436471,NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:59Z,2021-10-12T07:07:59Z,510
NCT04444674,NA,2020-06-15,NA,NA,2020-11-23,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 24, 2020",Actual,2020-06-24,November 2020,2020-11-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV","Active, not recruiting",NA,Phase 1/Phase 2,2130,Actual,University of Oxford,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.

De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2021-10-12T07:06:57Z,2021-10-12T07:06:57Z,406
NCT04437875,NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z,510
NCT04417335,NA,2020-05-25,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:31Z,2021-10-12T07:10:31Z,579
NCT04414267,NA,2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,NA,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:53Z,2021-10-12T07:10:53Z,239
NCT04412538,NA,2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z,580
NCT04405908,NA,2020-05-25,NA,NA,2021-01-11,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"June 19, 2020",Actual,2020-06-19,January 2021,2021-01-31,"May 25, 2021",Anticipated,2021-05-25,"October 16, 2020",Actual,2020-10-16,NA,Interventional,NA,NA,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.","Active, not recruiting",NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,NA,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z,357
NCT04383574,NA,2020-05-09,NA,NA,2021-08-16,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"July 30, 2022",Anticipated,2022-07-30,"December 28, 2021",Anticipated,2021-12-28,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:42Z,2021-10-12T07:14:42Z,140
NCT04380532,NA,2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,NA,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,591
NCT04384549,NA,2020-05-06,NA,NA,2020-08-17,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,"February 20, 2021",Anticipated,2021-02-20,"February 20, 2021",Anticipated,2021-02-20,NA,Interventional,COVID-BCG,NA,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and GuÃ©rin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,NA,Phase 3,1120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:33Z,2021-10-12T07:14:33Z,504
NCT04380701,NA,2020-05-06,NA,NA,2021-04-20,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",Recruiting,NA,Phase 1/Phase 2,476,Anticipated,BioNTech SE,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,258
NCT04373291,NA,2020-05-01,NA,NA,2021-10-07,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"May 18, 2020",Actual,2020-05-18,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-12T07:16:02Z,2021-10-12T07:16:02Z,88
NCT04372589,NA,2020-04-24,NA,NA,2021-07-26,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"May 20, 2020",Actual,2020-05-20,January 2021,2021-01-31,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,ATTACC,NA,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:10Z,2021-10-12T07:16:10Z,161
NCT04369794,NA,2020-04-27,NA,NA,2020-08-05,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 10, 2020",Anticipated,2020-08-10,August 2020,2020-08-31,August 2023,Anticipated,2023-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,BATTLE,NA,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z,516
NCT04352608,NA,2020-04-14,NA,NA,2021-07-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"April 16, 2020",Actual,2020-04-16,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z,161
NCT04348370,NA,2020-03-30,NA,NA,2021-10-05,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,BADAS,NA,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,"Active, not recruiting",NA,Phase 4,1800,Anticipated,Texas A&M University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,90
NCT04341389,NA,2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,NA,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:59Z,2021-10-12T07:19:59Z,599
NCT04324606,NA,2020-03-20,NA,NA,2021-04-08,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,NA,19,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:09Z,2021-10-12T07:22:09Z,270
NCT04328441,NA,2020-03-27,NA,NA,2021-05-09,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 25, 2020",Actual,2020-03-25,May 2021,2021-05-31,"May 30, 2021",Anticipated,2021-05-30,"March 31, 2021",Actual,2021-03-31,NA,Interventional,BCG-CORONA,NA,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.","Active, not recruiting",NA,Phase 3,1500,Anticipated,UMC Utrecht,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.

The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.",NA,NA,Yes,The results of this study will be disclosed unreservedly at the end of the study.,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,239
NCT04313127,NA,2020-03-15,NA,NA,2021-08-02,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,CTCOVID-19,NA,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2021-10-12T07:23:36Z,2021-10-12T07:23:36Z,154
NCT04299724,NA,2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,NA,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:25:19Z,2021-10-12T07:25:19Z,668
NCT04276896,NA,2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,NA,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z,657
NCT05075499,NA,2021-10-06,NA,NA,2021-10-06,2021-10-06,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-12,Estimate,"March 20, 2021",Actual,2021-03-20,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA),Recruiting,NA,Not Applicable,70,Anticipated,Sheba Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:42Z,2021-10-12T17:59:42Z,89
NCT05074368,NA,2021-08-24,NA,NA,2021-10-05,2021-10-05,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-12,Estimate,"July 6, 2021",Actual,2021-07-06,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,NA,Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination,Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination,"Active, not recruiting",NA,Not Applicable,500,Anticipated,National Taiwan University Hospital,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T17:59:53Z,2021-10-12T17:59:53Z,90
NCT04776317,NA,2021-02-25,NA,NA,2021-12-02,2021-02-25,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-03,Estimate,"March 25, 2021",Actual,2021-03-25,"August 17, 2021",2021-08-17,"September 19, 2022",Anticipated,2022-09-19,"September 19, 2022",Anticipated,2022-09-19,NA,Interventional,NA,NA,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1,147,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,17,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:35:55Z,2021-12-06T10:35:55Z,32
NCT04821674,NA,2021-03-25,NA,NA,2021-12-02,2021-03-25,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-03,Estimate,"March 15, 2021",Actual,2021-03-15,December 2021,2021-12-31,"December 31, 2022",Anticipated,2022-12-31,"August 13, 2021",Actual,2021-08-13,NA,Interventional,NA,NA,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,"A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects","Active, not recruiting",NA,Phase 1/Phase 2,152,Anticipated,"Daiichi Sankyo, Inc.",NA,10,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:35:01Z,2021-12-06T10:35:01Z,32
NCT04283461,NA,2020-02-21,NA,NA,2021-12-02,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-03,Estimate,"March 16, 2020",Actual,2020-03-16,"August 26, 2021",2021-08-26,"November 22, 2022",Anticipated,2022-11-22,"November 22, 2022",Anticipated,2022-11-22,NA,Interventional,NA,NA,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:43:47Z,2021-12-06T10:43:47Z,32
NCT04961541,NA,2021-07-09,NA,NA,2021-12-02,2021-07-09,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-06,Estimate,"September 8, 2021",Actual,2021-09-08,December 2021,2021-12-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,"A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1â„¢ Adjuvant in Healthy Participants â‰¥ 50 to â‰¤ 70 Years of Age","Active, not recruiting",NA,Phase 1/Phase 2,642,Actual,Novavax,NA,16,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T20:08:17Z,2021-12-06T20:08:17Z,32
NCT04852978,NA,2021-04-19,NA,NA,2021-12-03,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-12-03,2021-12-06,Estimate,"April 29, 2021",Actual,2021-04-29,December 2021,2021-12-31,"November 22, 2022",Anticipated,2022-11-22,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,NA,NA,"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","Active, not recruiting",NA,Phase 2,295,Actual,Regeneron Pharmaceuticals,NA,12,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-06T20:09:26Z,2021-12-06T20:09:26Z,31
NCT04583995,NA,2020-10-09,NA,NA,2021-12-02,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-06,Estimate,"November 28, 2020",Actual,2020-11-28,December 2021,2021-12-31,"January 14, 2022",Anticipated,2022-01-14,"January 14, 2022",Anticipated,2022-01-14,NA,Interventional,NA,NA,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom","Active, not recruiting",NA,Phase 3,15000,Anticipated,Novavax,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:12:06Z,2021-12-06T20:12:06Z,32
NCT04368988,NA,2020-04-24,NA,NA,2021-12-02,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-06,Estimate,"May 25, 2020",Actual,2020-05-25,December 2021,2021-12-31,"May 21, 2022",Anticipated,2022-05-21,"May 21, 2022",Anticipated,2022-05-21,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:42Z,2021-12-06T20:13:42Z,32
NCT05091307,NA,2021-10-01,NA,NA,2021-11-23,2021-10-22,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-12-07,Estimate,"November 2, 2021",Actual,2021-11-02,November 2021,2021-11-30,"August 12, 2022",Anticipated,2022-08-12,"January 6, 2022",Anticipated,2022-01-06,NA,Interventional,NA,NA,A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults,"A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,1680,Anticipated,Janssen Vaccines & Prevention B.V.,NA,4,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-08T10:21:35Z,2021-12-08T10:21:35Z,41
NCT05077176,NA,2021-10-13,NA,NA,2021-12-02,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-07,Estimate,"October 8, 2021",Actual,2021-10-08,November 2021,2021-11-30,"April 1, 2023",Anticipated,2023-04-01,"September 29, 2022",Anticipated,2022-09-29,NA,Interventional,NA,NA,Phase 3 Booster Vaccination Against COVID-19,"Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,7400,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-08T10:21:54Z,2021-12-08T10:21:54Z,32
NCT05033847,NA,2021-08-30,NA,NA,2021-11-23,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-12-07,Estimate,"September 12, 2021",Actual,2021-09-12,November 2021,2021-11-30,January 2024,Anticipated,2024-01-31,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,NA,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,NA,Phase 2,1800,Anticipated,"National Vaccine and Serum Institute, China",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:22:46Z,2021-12-08T10:22:46Z,41
NCT05007275,NA,2021-08-12,NA,NA,2021-12-06,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-12-06,2021-12-07,Estimate,"October 10, 2021",Actual,2021-10-10,December 2021,2021-12-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,COVAXAER01,NA,A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,A Phase I Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,Recruiting,NA,Phase 1,15,Anticipated,Imperial College London,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data will become available approximately 6 months from the last patient's last visit and remain available indefinitely.,According to study protocol.,NA,Yes,"The expectation is that after analysis the data from this study will be widely distributed in the medical and scientific community. Facilitated with presentations at local, national and international meetings, the hope is to publish widely in the medical literature. In addition, there is an excellent media department at Imperial College that will publicise research that has public interest when it is published.

The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Data from the study may also be used as part of a thesis for a PhD or MD.

All data will be anonymised and aggregated or pseudonymised; no identifying participant information will be published.",2021-12-08T10:23:13Z,2021-12-08T10:23:13Z,28
NCT04515147,NA,2020-08-13,NA,NA,2021-12-06,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-06,2021-12-07,Estimate,"September 28, 2020",Actual,2020-09-28,December 2021,2021-12-31,"February 18, 2022",Anticipated,2022-02-18,"February 18, 2022",Anticipated,2022-02-18,NA,Interventional,NA,NA,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age","Active, not recruiting",NA,Phase 2,674,Actual,CureVac AG,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-08T10:28:48Z,2021-12-08T10:28:48Z,28
NCT05148845,NA,2021-11-09,NA,NA,2021-12-04,2021-12-04,2021-12-08,Estimate,NA,NA,NA,NA,NA,NA,2021-12-04,2021-12-08,Estimate,"November 10, 2021",Actual,2021-11-10,December 2021,2021-12-31,June 2023,Anticipated,2023-06-30,"December 17, 2021",Anticipated,2021-12-17,NA,Interventional,Sisonke Boost,NA,Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.,"Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boostof Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)",Recruiting,NA,Phase 3,500000,Anticipated,Wits Health Consortium (Pty) Ltd,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of completion of study,on request,https://www.samrc.ac.za,Yes,"All study team scientists will disseminate the trial results as broadly as possible. Data will be shared with JNJ prior to release to the public. The study data will be published consistent with normal scientific practices.

The results from this research may also be disseminated through presentations at scientific institutions/ meetings, and/or publication in scientific journals. All publications will be uploaded to a publication repository. After sharing the results with study participants, they will be presented to communities from which participants are recruited, following Good Participatory Practice guidelines. The results will also be shared with global and local policy makers. Summary results of the trial will be made publicly available through the clinical trial registry. Any datasets used for analysis in publications can be requested by investigators via an online request to the organisation. Measures will be taken to protect identifiable information in the datasets",2021-12-09T09:11:14Z,2021-12-09T09:11:14Z,30
NCT05148962,NA,2021-12-03,NA,NA,2021-12-03,2021-12-03,2021-12-08,Estimate,NA,NA,NA,NA,NA,NA,2021-12-03,2021-12-08,Estimate,"September 16, 2021",Actual,2021-09-16,December 2021,2021-12-31,"November 4, 2022",Anticipated,2022-11-04,"November 4, 2022",Anticipated,2022-11-04,NA,Interventional,NA,NA,Study of GRT-R910 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Boost Vaccine in Healthy Volunteers,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of a Self-Amplifying mRNA Prophylactic Vaccine Boost Against SARS-CoV-2 in Previously Vaccinated Healthy Elderly Adults",Recruiting,NA,Phase 1,120,Anticipated,"Gritstone Oncology, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-09T09:11:10Z,2021-12-09T09:11:10Z,31
NCT05047640,NA,2021-09-13,NA,NA,2021-12-07,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-08,Estimate,"September 14, 2021",Actual,2021-09-14,December 2021,2021-12-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 3rd Dose Vaccine in Transplant Patients,"A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients",Recruiting,NA,Phase 3,200,Anticipated,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:14:29Z,2021-12-09T09:14:29Z,27
NCT04936997,NA,2021-06-18,NA,NA,2021-12-06,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-12-06,2021-12-08,Estimate,"June 7, 2021",Actual,2021-06-07,December 2021,2021-12-31,"February 1, 2027",Anticipated,2027-02-01,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,NA,NA,Immune Response to the COVID-19 Vaccine,Immune Response to the COVID-19 Vaccine,"Active, not recruiting",NA,Early Phase 1,1000,Anticipated,University of Arizona,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:15:41Z,2021-12-09T09:15:41Z,28
NCT04992260,NA,2021-08-03,NA,NA,2021-12-07,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-08,Estimate,"September 10, 2021",Actual,2021-09-10,July 2021,2021-07-31,"April 1, 2023",Anticipated,2023-04-01,"May 25, 2022",Anticipated,2022-05-25,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase â…¢ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years",Recruiting,NA,Phase 3,14000,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:15:15Z,2021-12-09T09:15:15Z,27
NCT04818801,NA,2021-03-19,NA,NA,2021-12-06,2021-03-23,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-06,2021-12-08,Estimate,"June 18, 2021",Actual,2021-06-18,December 2021,2021-12-31,July 2022,Anticipated,2022-07-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects","Active, not recruiting",NA,Early Phase 1,99,Actual,"Jiangsu Rec-Biotechnology Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:17:03Z,2021-12-09T09:17:03Z,28
NCT04847050,NA,2021-04-14,NA,NA,2021-12-08,2021-04-14,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-12-08,2021-12-09,Estimate,"April 28, 2021",Actual,2021-04-28,"December 6, 2021",2021-12-06,"February 25, 2023",Anticipated,2023-02-25,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,NA,NA,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...","A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine",Recruiting,NA,Phase 2,220,Anticipated,National Institutes of Health Clinical Center (CC),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-10T11:36:10Z,2021-12-10T11:36:10Z,26
NCT04715997,NA,2021-01-18,NA,NA,2021-11-25,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-12-09,Estimate,"December 30, 2020",Actual,2020-12-30,November 2021,2021-11-30,"June 30, 2022",Anticipated,2022-06-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,170,Anticipated,"Genexine, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:37:42Z,2021-12-10T11:37:42Z,39
NCT04445389,NA,2020-06-19,NA,NA,2021-11-25,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-12-09,Estimate,"June 17, 2020",Actual,2020-06-17,November 2021,2021-11-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,60,Actual,"Genexine, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:41:07Z,2021-12-10T11:41:07Z,39
NCT05124171,NA,2021-11-08,NA,NA,2021-12-09,2021-11-16,2021-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-09,2021-12-10,Estimate,"December 8, 2021",Actual,2021-12-08,December 2021,2021-12-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,COVIBOOST,NA,Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination,"Immunogenicity and Reactogenicity Following a 3rd Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered as a Booster in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination: A Randomized, Single-blinded Multicenter Clinical Trial",Recruiting,NA,Phase 3,300,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:16:26Z,2021-12-13T10:16:26Z,25
NCT04785144,NA,2021-03-04,NA,NA,2021-12-09,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-12-09,2021-12-10,Estimate,"March 29, 2021",Actual,2021-03-29,"April 6, 2021",2021-04-06,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults","Active, not recruiting",NA,Phase 1,135,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-13T10:21:14Z,2021-12-13T10:21:14Z,25
NCT05047770,NA,2021-09-15,NA,NA,2021-12-10,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-10,2021-12-13,Estimate,"October 7, 2021",Actual,2021-10-07,December 2021,2021-12-31,"July 27, 2022",Anticipated,2022-07-27,"March 29, 2022",Anticipated,2022-03-29,NA,Interventional,NA,NA,A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine,"A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination","Active, not recruiting",NA,Phase 3,1546,Anticipated,GlaxoSmithKline,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-12-14T09:35:20Z,2021-12-14T09:35:20Z,24
NCT04973449,NA,2021-07-02,NA,NA,2021-12-10,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-12-10,2021-12-13,Estimate,"June 27, 2021",Actual,2021-06-27,December 2021,2021-12-31,"July 13, 2022",Anticipated,2022-07-13,"January 26, 2022",Anticipated,2022-01-26,NA,Interventional,AZD2816,NA,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,2849,Anticipated,AstraZeneca,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

URL:

https://astrazenecagroup-dt.pharmacm.com/DT/Home",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-14T09:36:18Z,2021-12-14T09:36:18Z,24
NCT05157178,NA,2021-12-10,NA,NA,2021-12-10,2021-12-10,2021-12-14,Estimate,NA,NA,NA,NA,NA,NA,2021-12-10,2021-12-14,Estimate,"June 20, 2021",Actual,2021-06-20,December 2021,2021-12-31,"June 27, 2022",Anticipated,2022-06-27,"February 11, 2022",Anticipated,2022-02-11,NA,Interventional,NA,NA,Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.,Immunogenicity Study of the Covid-19 (Recombinante) Vaccine - Fiocruz/AstraZeneca When Administered With a 4 or 8 Weeks Interval Between the First Two Doses.,"Active, not recruiting",NA,Phase 4,1264,Actual,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:29Z,2021-12-15T09:08:29Z,24
NCT05157230,NA,2021-12-11,NA,NA,2021-12-11,2021-12-11,2021-12-14,Estimate,NA,NA,NA,NA,NA,NA,2021-12-11,2021-12-14,Estimate,"September 1, 2021",Actual,2021-09-01,December 2021,2021-12-31,"December 25, 2021",Anticipated,2021-12-25,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,NA,Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination,Evaluation of Deltoid Muscle Exercises on Injection Site and Arm Pain After Pfizer - BioNTech (BNT162b2) COVID - 19 Vaccination,Recruiting,NA,Not Applicable,300,Anticipated,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:26Z,2021-12-15T09:08:26Z,23
NCT05112913,NA,2021-11-08,NA,NA,2021-12-13,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"July 27, 2021",Actual,2021-07-27,October 2021,2021-10-31,"June 25, 2022",Anticipated,2022-06-25,"November 17, 2021",Actual,2021-11-17,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰Between Different Workshops for Prevention of COVID-19 in Healthy Children Aged 3-17 Years","Active, not recruiting",NA,Phase 4,2520,Anticipated,"Sinovac Biotech Co., Ltd",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:10:31Z,2021-12-15T09:10:31Z,21
NCT05156723,NA,2021-11-26,NA,NA,2021-12-13,2021-12-13,2021-12-14,Estimate,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"July 19, 2021",Actual,2021-07-19,November 2021,2021-11-30,"May 30, 2022",Anticipated,2022-05-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,NA,"The Objectives of This Study Are Study the Immunogenicity, Safety and Tolerability of the Coronavirus Vaccine in Healthy Adult Volunteer Aged 18 to 60 Years.","A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 Years","Active, not recruiting",NA,Phase 1/Phase 2,155,Anticipated,St. Petersburg Research Institute of Vaccines and Sera,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:56Z,2021-12-15T09:08:56Z,21
NCT05137418,NA,2021-11-26,NA,NA,2021-12-13,2021-11-26,2021-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"November 27, 2021",Actual,2021-11-27,November 2021,2021-11-30,"February 27, 2023",Anticipated,2023-02-27,"February 27, 2022",Anticipated,2022-02-27,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","An Open-labelled, Bridging Phase â…¢ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years","Active, not recruiting",NA,Phase 3,1000,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:10:09Z,2021-12-15T09:10:09Z,21
NCT04904744,NA,2021-05-25,NA,NA,2021-12-13,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-13,2021-12-14,Estimate,"May 28, 2021",Actual,2021-05-28,December 2021,2021-12-31,"December 10, 2021",Actual,2021-12-10,"October 31, 2021",Actual,2021-10-31,NA,Interventional,NA,NA,"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination",Completed,NA,Not Applicable,1235,Actual,"Children's Hospital Medical Center, Cincinnati",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:13:24Z,2021-12-15T09:13:24Z,21
NCT05158855,NA,2021-12-14,NA,NA,2021-12-14,2021-12-14,2021-12-15,Estimate,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-15,Estimate,"June 1, 2021",Actual,2021-06-01,December 2021,2021-12-31,"July 30, 2022",Anticipated,2022-07-30,"April 20, 2022",Anticipated,2022-04-20,NA,Interventional,NA,NA,Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine,Human Pilot Test of an Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine,Recruiting,NA,Not Applicable,30,Anticipated,DreamTec Research Limited,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:09:45Z,2021-12-16T09:09:45Z,20
NCT05030974,NA,2021-08-20,NA,NA,2021-11-30,2021-08-26,2021-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-30,2021-12-15,Estimate,"October 21, 2021",Actual,2021-10-21,November 2021,2021-11-30,January 2023,Anticipated,2023-01-31,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,RECOVAC Third Vaccination Study,"Optimal Third Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium",Recruiting,NA,Phase 4,460,Anticipated,University Medical Center Groningen,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The data of this study will be available from the principal investigator, upon reasonable request.",2021-12-16T09:13:25Z,2021-12-16T09:13:25Z,34
NCT05022472,NA,2021-08-18,NA,NA,2021-12-14,2021-08-24,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"July 16, 2021",Actual,2021-07-16,December 2021,2021-12-31,"January 31, 2026",Anticipated,2026-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,2VIDA!,NA,Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California,Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California,Recruiting,NA,Phase 4,1000,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:16:31Z,2021-12-17T09:16:31Z,20
NCT05160766,NA,2021-11-11,NA,NA,2021-12-14,2021-12-14,2021-12-16,Estimate,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"November 8, 2021",Actual,2021-11-08,December 2021,2021-12-31,May 2023,Anticipated,2023-05-31,April 2022,Anticipated,2022-04-30,NA,Interventional,EU-COVAT-1,NA,Assessing Immune Response of Different COVID-19 Vaccines in Older Adults,"A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (â‰¥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)",Recruiting,NA,Phase 2,600,Anticipated,University of Cologne,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:11:27Z,2021-12-17T09:11:27Z,20
NCT05132855,NA,2021-11-11,NA,NA,2021-12-06,2021-11-22,2021-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-12-06,2021-12-16,Estimate,"November 30, 2021",Actual,2021-11-30,November 2021,2021-11-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,NA,NA,The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine,"Safety, Reactogenicity, and Immunogenicity of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine: a Single-blind and Randomized Study",Recruiting,NA,Phase 1/Phase 2,400,Anticipated,Chang Gung Memorial Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:14:02Z,2021-12-17T09:14:02Z,28
NCT05000216,NA,2021-08-06,NA,NA,2021-12-15,2021-08-06,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-16,Estimate,"August 13, 2021",Actual,2021-08-13,December 2021,2021-12-31,December 2022,Anticipated,2022-12-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01),Recruiting,NA,Phase 2,600,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-12-17T09:16:49Z,2021-12-17T09:16:49Z,19
NCT04967742,NA,2021-07-12,NA,NA,2021-12-15,2021-07-15,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-16,Estimate,"August 5, 2021",Actual,2021-08-05,September 2021,2021-09-30,"October 31, 2021",Actual,2021-10-31,"August 22, 2021",Actual,2021-08-22,NA,Interventional,NA,NA,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,50,Actual,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:17:19Z,2021-12-17T09:17:19Z,19
NCT04690387,NA,2020-12-28,NA,NA,2021-12-14,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"December 7, 2020",Actual,2020-12-07,December 2021,2021-12-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,NA,Interventional,NA,NA,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:21:07Z,2021-12-17T09:21:07Z,20
NCT05067933,NA,2021-09-16,NA,NA,2021-12-15,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-12-15,2021-12-17,Estimate,"October 1, 2021",Actual,2021-10-01,December 2021,2021-12-31,June 2023,Anticipated,2023-06-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally",Recruiting,NA,Phase 2,896,Anticipated,Vaxart,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:14:37Z,2021-12-18T09:14:37Z,19
NCT04889209,NA,2021-05-13,NA,NA,2021-12-02,2021-05-13,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-02,2021-12-17,Estimate,"May 28, 2021",Actual,2021-05-28,"November 23, 2021",2021-11-23,"December 1, 2022",Anticipated,2022-12-01,"December 1, 2022",Anticipated,2022-12-01,NA,Interventional,NA,NA,Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,Recruiting,NA,Phase 1/Phase 2,950,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-18T09:17:34Z,2021-12-18T09:17:34Z,32
NCT05163743,NA,2021-12-16,NA,NA,2021-12-16,2021-12-16,2021-12-20,Estimate,NA,NA,NA,NA,NA,NA,2021-12-16,2021-12-20,Estimate,"May 23, 2021",Actual,2021-05-23,December 2021,2021-12-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Diet and COVID-19 Vaccination,COVID-19 Vaccination in Subjects With Obesity: Impact of Metabolic Health and the Role of a Ketogenic Diet,Recruiting,NA,Not Applicable,24,Anticipated,University of Roma La Sapienza,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:12:01Z,2021-12-21T09:12:01Z,18
NCT04969250,NA,2021-07-16,NA,NA,2021-12-17,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"August 25, 2021",Actual,2021-08-25,December 2021,2021-12-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,Vaccination for Recovered Inpatients With COVID-19 (VATICO),SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients,Recruiting,NA,Phase 4,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-21T09:16:28Z,2021-12-21T09:16:28Z,17
NCT04816669,NA,2021-03-24,NA,NA,2021-12-17,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"April 1, 2021",Actual,2021-04-01,December 2021,2021-12-31,"December 1, 2021",Actual,2021-12-01,"December 1, 2021",Actual,2021-12-01,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE",Completed,NA,Phase 3,629,Actual,BioNTech SE,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:18:14Z,2021-12-21T09:18:14Z,17
NCT04681092,NA,2020-12-22,NA,NA,2021-12-09,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-12-09,2021-12-20,Estimate,"April 6, 2021",Actual,2021-04-06,December 2021,2021-12-31,"May 30, 2022",Anticipated,2022-05-30,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,ACT,NA,Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study,"Active, not recruiting",NA,Phase 1/Phase 2,112,Actual,University Medical Center Groningen,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:19:22Z,2021-12-21T09:19:22Z,25
NCT04588480,NA,2020-10-14,NA,NA,2021-12-17,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-12-17,2021-12-20,Estimate,"October 21, 2020",Actual,2020-10-21,December 2021,2021-12-31,"November 25, 2021",Actual,2021-11-25,"November 25, 2021",Actual,2021-11-25,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS",Completed,NA,Phase 1/Phase 2,160,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:20:13Z,2021-12-21T09:20:13Z,17
NCT05165966,NA,2021-12-20,NA,NA,2021-12-20,2021-12-20,2021-12-21,Estimate,NA,NA,NA,NA,NA,NA,2021-12-20,2021-12-21,Estimate,"October 20, 2021",Actual,2021-10-20,December 2021,2021-12-31,"June 20, 2022",Anticipated,2022-06-20,"February 20, 2022",Anticipated,2022-02-20,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","A Randomized, Double-Blinded Clinical Trial to Evaluate the Immunogenicity Using Additional Dose of Medium-dosage or High-dosage COVID-19 Vaccine (Vero Cell), Inactivated in Populations Who Have Completed Primary Immunization 5-9 Months","Active, not recruiting",NA,Phase 4,340,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:10:34Z,2021-12-22T09:10:34Z,14
NCT05096832,NA,2021-10-21,NA,NA,2021-12-19,2021-10-25,2021-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-19,2021-12-21,Estimate,"November 3, 2021",Actual,2021-11-03,December 2021,2021-12-31,"March 14, 2023",Anticipated,2023-03-14,"January 27, 2023",Anticipated,2023-01-27,NA,Interventional,COVID-19,NA,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",Recruiting,NA,Phase 3,10722,Anticipated,Livzon Pharmaceutical Group Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:13:14Z,2021-12-22T09:13:14Z,15
NCT04904471,NA,2021-05-26,NA,NA,2021-12-19,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-19,2021-12-21,Estimate,"June 15, 2021",Actual,2021-06-15,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells),"A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells), for the Prevention of COVID-19 in Adults Aged 18 Years and Older",Enrolling by invitation,NA,Phase 3,40000,Anticipated,"WestVac Biopharma Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:15:47Z,2021-12-22T09:15:47Z,15
NCT04860297,NA,2021-04-21,NA,NA,2021-12-18,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-18,2021-12-21,Estimate,"April 16, 2021",Actual,2021-04-16,December 2021,2021-12-31,"March 31, 2023",Anticipated,2023-03-31,"March 31, 2023",Anticipated,2023-03-31,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,"A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls",Recruiting,NA,Phase 3,240,Anticipated,"ModernaTX, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:16:25Z,2021-12-22T09:16:25Z,16
NCT04792567,NA,2021-03-08,NA,NA,2021-12-20,2021-03-08,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-12-20,2021-12-21,Estimate,"April 19, 2021",Actual,2021-04-19,December 2021,2021-12-31,"April 2, 2022",Anticipated,2022-04-02,"January 17, 2022",Anticipated,2022-01-17,NA,Interventional,AMA-VACC,NA,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod),"Active, not recruiting",NA,Phase 4,41,Actual,Novartis,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-12-22T09:17:07Z,2021-12-22T09:17:07Z,14
NCT04788459,NA,2021-03-01,NA,NA,2021-12-20,2021-03-05,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-12-20,2021-12-21,Estimate,"February 25, 2021",Actual,2021-02-25,December 2021,2021-12-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,160,Anticipated,Takis,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:17:10Z,2021-12-22T09:17:10Z,14
NCT04796896,NA,2021-03-11,NA,NA,2021-12-18,2021-03-11,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-12-18,2021-12-21,Estimate,"March 15, 2021",Actual,2021-03-15,December 2021,2021-12-31,"June 12, 2023",Anticipated,2023-06-12,"June 12, 2023",Anticipated,2023-06-12,NA,Interventional,NA,NA,A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,"A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age",Recruiting,NA,Phase 2/Phase 3,13275,Anticipated,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:17:06Z,2021-12-22T09:17:06Z,16
NCT04470427,NA,2020-07-11,NA,NA,2021-12-18,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-12-18,2021-12-21,Estimate,"July 27, 2020",Actual,2020-07-27,December 2021,2021-12-31,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2022",Anticipated,2022-10-27,NA,Interventional,NA,NA,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,30000,Actual,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:19:53Z,2021-12-22T09:19:53Z,16
NCT05148949,NA,2021-12-03,NA,NA,2021-12-23,2021-12-03,2021-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-28,Estimate,"December 22, 2021",Actual,2021-12-22,December 2021,2021-12-31,"August 10, 2022",Anticipated,2022-08-10,"May 10, 2022",Anticipated,2022-05-10,NA,Interventional,NA,NA,Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients,"Safety and Immunogenicity of Three Doses of an Inactivated SARS-CoV-2 Vaccine in Chinese Pulmonary Tuberculosis Patients Aged 18-75 Years: a Randomized, Double-blind, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,240,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:21:53Z,2021-12-29T08:21:53Z,11
NCT05135585,NA,2021-11-23,NA,NA,2021-12-23,2021-11-24,2021-11-26,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"December 1, 2021",Actual,2021-12-01,October 2021,2021-10-31,"October 12, 2022",Anticipated,2022-10-12,"October 12, 2022",Anticipated,2022-10-12,NA,Interventional,COVCAL,NA,Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population,Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population,Recruiting,NA,Not Applicable,660,Anticipated,Institut Pasteur,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:22:48Z,2021-12-29T08:22:48Z,11
NCT05097053,NA,2021-10-17,NA,NA,2021-12-07,2021-10-18,2021-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-23,Actual,"October 7, 2021",Actual,2021-10-07,December 2021,2021-12-31,July 2022,Anticipated,2022-07-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19,"A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months",Recruiting,NA,Phase 4,200,Anticipated,Taoyuan General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:24:37Z,2021-12-29T08:24:37Z,27
NCT05087173,NA,2021-10-20,NA,NA,2021-12-25,2021-10-20,2021-10-21,Actual,NA,NA,NA,NA,NA,NA,2021-12-25,2021-12-28,Estimate,"October 11, 2021",Actual,2021-10-11,December 2021,2021-12-31,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Recruiting,NA,Not Applicable,1200,Anticipated,Sun Yat-sen University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:25:01Z,2021-12-29T08:25:01Z,9
NCT05067894,NA,2021-10-01,NA,NA,2021-12-22,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-12-22,2021-12-27,Actual,"December 10, 2021",Actual,2021-12-10,December 2021,2021-12-31,April 2022,Anticipated,2022-04-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine,"A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Populations Aged 18 Years and Above in Indonesia",Recruiting,NA,Phase 1,60,Anticipated,PT Bio Farma,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:25:42Z,2021-12-29T08:25:42Z,12
NCT05057923,NA,2021-09-21,2021-12-18,NA,2021-12-22,2021-09-23,2021-09-27,Actual,2021-12-22,2021-12-23,Actual,NA,NA,NA,2021-12-22,2021-12-23,Actual,"July 10, 2021",Actual,2021-07-10,December 2021,2021-12-31,"November 1, 2021",Actual,2021-11-01,"October 20, 2021",Actual,2021-10-20,NA,Interventional,NA,The baseline population does not differ from the participant flow.,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Completed,NA,Not Applicable,9,Actual,DreamTec Research Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:59Z,2021-12-29T08:25:59Z,12
NCT04955626,NA,2021-06-09,NA,NA,2021-12-21,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"July 1, 2021",Actual,2021-07-01,December 2021,2021-12-31,"September 20, 2023",Anticipated,2023-09-20,"September 20, 2023",Anticipated,2023-09-20,NA,Interventional,NA,NA,"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a Booster Dose of BNT162b2 Against COVID-19 in Participants â‰¥12 Years of Age.",A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2,"Active, not recruiting",NA,Phase 3,10000,Anticipated,BioNTech SE,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:28:35Z,2021-12-29T08:28:35Z,13
NCT05057169,NA,2021-09-24,NA,NA,2021-12-21,2021-09-24,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"November 18, 2021",Actual,2021-11-18,December 2021,2021-12-31,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2023",Anticipated,2023-03-31,NA,Interventional,NA,NA,Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study),Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study),Recruiting,NA,Phase 4,400,Anticipated,The University of Hong Kong,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-29T08:26:04Z,2021-12-29T08:26:04Z,13
NCT04951310,NA,2021-06-16,NA,NA,2021-12-21,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"June 7, 2021",Actual,2021-06-07,December 2021,2021-12-31,"August 14, 2021",Actual,2021-08-14,"August 14, 2021",Actual,2021-08-14,NA,Interventional,NA,NA,COVID-19 Vaccinations With a Sweepstakes,COVID-19 Vaccinations With a Sweepstakes,Completed,NA,Not Applicable,1241810,Actual,University of Pennsylvania,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:28:39Z,2021-12-29T08:28:39Z,13
NCT04816643,NA,2021-03-19,NA,NA,2021-12-21,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"March 24, 2021",Actual,2021-03-24,December 2021,2021-12-31,"May 5, 2026",Anticipated,2026-05-05,"May 5, 2026",Anticipated,2026-05-05,NA,Interventional,NA,NA,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults","PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN and Young Adults",Recruiting,NA,Phase 2/Phase 3,11422,Anticipated,BioNTech SE,NA,22,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:31:22Z,2021-12-29T08:31:22Z,13
NCT04758962,NA,2021-02-08,NA,NA,2021-12-23,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"February 15, 2021",Actual,2021-02-15,December 2021,2021-12-31,"May 2, 2022",Anticipated,2022-05-02,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,"A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age","Active, not recruiting",NA,Phase 1,10,Actual,GlaxoSmithKline,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-12-29T08:32:36Z,2021-12-29T08:32:36Z,11
NCT04762680,NA,2021-02-18,NA,NA,2021-12-27,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-12-27,2021-12-28,Estimate,"February 24, 2021",Actual,2021-02-24,December 2021,2021-12-31,"March 30, 2023",Anticipated,2023-03-30,"March 30, 2023",Anticipated,2023-03-30,NA,Interventional,VAT00002,NA,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),Recruiting,NA,Phase 2/Phase 3,5414,Anticipated,Sanofi,NA,15,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-29T08:32:31Z,2021-12-29T08:32:31Z,7
NCT04537208,NA,2020-09-02,NA,NA,2021-12-23,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-12-23,2021-12-27,Actual,"September 3, 2020",Actual,2020-09-03,December 2021,2021-12-31,"November 19, 2021",Actual,2021-11-19,"November 19, 2021",Actual,2021-11-19,NA,Interventional,NA,NA,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,Completed,NA,Phase 1/Phase 2,442,Actual,Sanofi,NA,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-29T08:36:50Z,2021-12-29T08:36:50Z,11
NCT04535453,NA,2020-08-27,NA,NA,2021-12-21,2020-08-27,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"August 28, 2020",Actual,2020-08-28,December 2021,2021-12-31,"March 28, 2022",Anticipated,2022-03-28,"March 28, 2022",Anticipated,2022-03-28,NA,Interventional,NA,NA,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive","Active, not recruiting",NA,Phase 2,635,Actual,Janssen Vaccines & Prevention B.V.,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:36:51Z,2021-12-29T08:36:51Z,13
NCT04523246,NA,2020-08-20,NA,NA,2021-12-07,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-12-07,2021-12-23,Actual,"September 1, 2020",Actual,2020-09-01,December 2021,2021-12-31,"September 30, 2022",Anticipated,2022-09-30,"November 30, 2021",Actual,2021-11-30,NA,Interventional,NH-Shingrix,NA,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study","Active, not recruiting",NA,Early Phase 1,217,Actual,University of Oklahoma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:37:00Z,2021-12-29T08:37:00Z,27
NCT04498247,NA,2020-08-03,2021-12-20,NA,2021-12-20,2020-08-03,2020-08-04,Actual,2021-12-20,2021-12-23,Actual,NA,NA,NA,2021-12-20,2021-12-23,Actual,"August 27, 2020",Actual,2020-08-27,December 2021,2021-12-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Terminated,NA,Phase 1/Phase 2,263,Actual,Merck Sharp & Dohme Corp.,NA,10,NA,The study was terminated based on an interim assessment of immunogenicity,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-29T08:37:21Z,2021-12-29T08:37:21Z,14
NCT04368728,NA,2020-04-27,NA,NA,2021-12-21,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-12-21,2021-12-22,Actual,"April 29, 2020",Actual,2020-04-29,December 2021,2021-12-31,"May 15, 2023",Anticipated,2023-05-15,"May 15, 2023",Anticipated,2023-05-15,NA,Interventional,NA,NA,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 2/Phase 3,43998,Anticipated,BioNTech SE,NA,20,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:39:12Z,2021-12-29T08:39:12Z,13
NCT05168813,NA,2021-12-21,NA,NA,2021-12-28,2021-12-21,2021-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-12-28,2021-12-29,Actual,"December 1, 2021",Actual,2021-12-01,December 2021,2021-12-31,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2023",Anticipated,2023-06-01,NA,Interventional,CoVPN3008,NA,Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern,"Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern",Recruiting,NA,Phase 2/Phase 3,14000,Anticipated,COVID-19 Prevention Network,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-30T20:34:51Z,2021-12-30T20:34:51Z,6
NCT04999111,NA,2021-08-03,NA,NA,2021-12-22,2021-08-03,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-12-22,2021-12-30,Estimate,"August 6, 2021",Actual,2021-08-06,December 2021,2021-12-31,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2021",Actual,2021-10-27,NA,Interventional,Amplify,NA,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2","Active, not recruiting",NA,Phase 2,1540,Anticipated,Janssen Vaccines & Prevention B.V.,NA,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-30T20:39:01Z,2021-12-30T20:39:01Z,12
NCT04569786,NA,2020-09-24,2021-12-22,NA,2021-12-22,2020-09-24,2020-09-30,Actual,2021-12-22,2021-12-29,Actual,NA,NA,NA,2021-12-22,2021-12-29,Actual,"October 29, 2020",Actual,2020-10-29,December 2021,2021-12-31,"February 18, 2021",Actual,2021-02-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,NA,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults",Terminated,NA,Phase 1,232,Actual,Merck Sharp & Dohme Corp.,NA,9,NA,The study was terminated based on an interim assessment of immunogenicity.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-30T20:44:05Z,2021-12-30T20:44:05Z,12
NCT04951323,NA,2021-06-02,NA,NA,2021-10-12,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"March 22, 2021",Actual,2021-03-22,October 2021,2021-10-31,"January 1, 2023",Anticipated,2023-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,NA,Phase 3,50,Anticipated,University of Liege,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:02:06Z,2021-10-13T20:02:06Z,83
NCT04379336,NA,2020-05-04,NA,NA,2021-10-12,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"May 4, 2020",Actual,2020-05-04,October 2021,2021-10-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 3,1000,Actual,TASK Applied Science,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2021-10-13T20:06:03Z,2021-10-13T20:06:03Z,83
NCT05079152,NA,2021-10-05,NA,NA,2021-10-05,2021-10-05,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-15,Estimate,"May 6, 2021",Actual,2021-05-06,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,"May 29, 2021",Actual,2021-05-29,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)","Active, not recruiting",NA,Phase 4,1404,Actual,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:58:54Z,2021-10-15T21:58:54Z,90
NCT04930965,NA,2021-06-16,NA,NA,2021-10-12,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"October 5, 2021",Actual,2021-10-05,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate,Louisiana Community-Engagement Alliance Against COVID-19 Disparities (LA-CEAL): Impact of HALT COVID Ambassador Program on Likelihood to Vaccinate,Recruiting,NA,Not Applicable,100,Anticipated,Tulane University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:04:25Z,2021-10-15T22:04:25Z,83
NCT05047445,NA,2021-08-27,NA,NA,2021-10-06,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,"A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)",Recruiting,NA,Phase 1,40,Anticipated,Scancell Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make individual patient data available.,2021-10-15T22:01:48Z,2021-10-15T22:01:48Z,89
NCT04750343,NA,2021-02-10,NA,NA,2021-10-14,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"February 3, 2021",Actual,2021-02-03,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,"July 28, 2021",Actual,2021-07-28,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,328,Actual,"SK Bioscience Co., Ltd.",NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:15Z,2021-10-15T22:07:15Z,81
NCT04641858,NA,2020-11-22,NA,NA,2021-10-14,2020-11-22,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"December 3, 2020",Actual,2020-12-03,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,June 2022,Anticipated,2022-06-30,NA,Interventional,EDCTP,NA,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT),Recruiting,NA,Phase 4,1050,Anticipated,University of Southern Denmark,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed.,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to ifronteira@ihmt.unl.pt,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to professor InÃªs Fronteira ifronteira@ihmt.unl.pt,2021-10-15T22:08:50Z,2021-10-15T22:08:50Z,81
NCT04742738,NA,2021-02-04,NA,NA,2021-10-14,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"January 20, 2021",Actual,2021-01-20,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,260,Actual,"SK Bioscience Co., Ltd.",NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:19Z,2021-10-15T22:07:19Z,81
NCT04715438,NA,2021-01-11,NA,NA,2021-10-05,2021-01-15,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"January 8, 2021",Actual,2021-01-08,October 2021,2021-10-31,April 2023,Anticipated,2023-04-30,"June 4, 2021",Actual,2021-06-04,NA,Interventional,VOICE,NA,Vaccination Against COVID-19 in Cancer,Vaccination Against cOvid In CancEr,"Active, not recruiting",NA,Not Applicable,791,Actual,University Medical Center Groningen,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,we start the make interim results available second half of 2021,"we aim to share as much as possible also through own website, and COVID-19 platforms that are considered for this kind of research",NA,Yes,"Alignment and reuse Our options for reusing data, biological materials, and/or other resources (from research or practice) in your project.

Data: Clinicopathological parameters as described in the protocol
Biological materials: Blood
Research software: R statistical package, Castor, MOLGENIS
Other resources, i.e.,Nederlandse Kankerregistratie (NKR), the Dutch Cancer Registry, electronic patient dossiers (EPDs)

FAIR data within the COVID-19 research community

A COVID-19 related or other Findability, Accessibility, Interoperability, and Reuse (FAIR) data points
COVID-19 research platform for data sharing

we will make protocol etc. available on the website soon voicetrial.nl",2021-10-15T22:07:44Z,2021-10-15T22:07:44Z,90
NCT05012943,NA,2021-08-13,NA,NA,2021-10-15,2021-08-13,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"August 15, 2021",Actual,2021-08-15,October 2021,2021-10-31,"August 31, 2023",Anticipated,2023-08-31,"February 28, 2023",Anticipated,2023-02-28,NA,Interventional,ARCT-154-01,NA,The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01),"A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults",Recruiting,NA,Phase 2/Phase 3,21000,Anticipated,Vinbiocare Biotechnology Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is the sole property of VinBioCare. VinBioCare may share a copy of the study IPD with their collaborative partners if requested.,2021-10-19T10:07:13Z,2021-10-19T10:07:13Z,80
NCT04838795,NA,2021-02-17,NA,NA,2021-10-13,2021-04-06,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-18,Estimate,"February 18, 2021",Actual,2021-02-18,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,Sisonke,NA,Sisonke (Together): OPEN LABEL TRIAL COVID-19,"Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)",Recruiting,NA,Phase 3,500000,Anticipated,Wits Health Consortium (Pty) Ltd,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-19T10:09:20Z,2021-10-19T10:09:20Z,82
NCT04522089,NA,2020-08-12,NA,NA,2021-10-14,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"August 24, 2020",Actual,2020-08-24,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"November 20, 2020",Actual,2020-11-20,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers","Active, not recruiting",NA,Phase 1,70,Anticipated,Adimmune Corporation,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-19T10:12:06Z,2021-10-19T10:12:06Z,81
NCT04951336,NA,2021-06-30,NA,NA,2021-10-11,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-19,Estimate,"June 10, 2021",Actual,2021-06-10,October 2021,2021-10-31,"June 1, 2022",Anticipated,2022-06-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,MACH19,NA,RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination,"Multicenter Double-Blind, Placebo-Controlled RCT of Fomitopsis Officinalis/Trametes Versicolor for COVID-19",Recruiting,NA,Not Applicable,66,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:08:51Z,2021-10-20T11:08:51Z,84
NCT04942405,NA,2021-06-24,NA,NA,2021-10-18,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"June 21, 2021",Actual,2021-06-21,June 2021,2021-06-30,"March 31, 2023",Anticipated,2023-03-31,"January 21, 2022",Anticipated,2022-01-21,NA,Interventional,NA,NA,"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial",Recruiting,NA,Phase 3,40800,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:09:02Z,2021-10-20T11:09:02Z,77
NCT04852861,NA,2021-04-14,NA,NA,2021-10-18,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 10, 2021",Actual,2021-05-10,October 2021,2021-10-31,"September 30, 2022",Anticipated,2022-09-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,REDU-VAC,NA,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population,Enrolling by invitation,NA,Phase 4,150,Anticipated,Sciensano,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:10:05Z,2021-10-20T11:10:05Z,77
NCT05085145,NA,2021-08-20,NA,NA,2021-10-18,2021-10-18,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-20,Actual,"September 1, 2021",Actual,2021-09-01,August 2021,2021-08-31,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,NA,Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV,The Efficacy of COVID-19 Vaccine in Patients With HIV Infectionï¼Œa Prospective and Multicenter Clinical Trial,Recruiting,NA,Phase 4,200,Anticipated,Beijing 302 Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:02:26Z,2021-10-22T11:02:26Z,77
NCT05028257,NA,2021-07-31,NA,NA,2021-10-15,2021-08-30,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-20,Actual,"September 15, 2021",Actual,2021-09-15,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,COVALL,NA,Allergy and COVID-19 Vaccines,Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines,Recruiting,NA,Phase 3,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:05:07Z,2021-10-22T11:05:07Z,80
NCT04952376,NA,2021-06-07,NA,NA,2021-10-19,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,January 2022,Anticipated,2022-01-31,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Equitable Access to COVID-19 Vaccines,Enabling Equitable Access to COVID-19 Vaccine in Under-Resourced Communities,Recruiting,NA,Not Applicable,1500,Anticipated,Mayo Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:06:39Z,2021-10-22T11:06:39Z,76
NCT04790851,NA,2021-03-08,NA,NA,2021-10-12,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"March 10, 2021",Actual,2021-03-10,October 2021,2021-10-31,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:09:15Z,2021-10-22T11:09:15Z,83
NCT04400838,NA,2020-05-12,NA,NA,2021-10-14,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-20,Actual,"May 28, 2020",Actual,2020-05-28,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Active, not recruiting",NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,NA,29,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:14:03Z,2021-10-22T11:14:03Z,81
NCT05089045,NA,2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,NA,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,Not Applicable,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:52Z,2021-10-25T10:35:52Z,74
NCT05007951,NA,2021-08-09,NA,NA,2021-10-14,2021-08-09,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19),"A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,3990,Anticipated,"SK Bioscience Co., Ltd.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:37:47Z,2021-10-25T10:37:47Z,81
NCT05077267,NA,2021-10-11,NA,NA,2021-10-14,2021-10-11,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 19, 2021",Actual,2021-08-19,October 2021,2021-10-31,"February 1, 2024",Anticipated,2024-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects",Recruiting,NA,Phase 2,210,Anticipated,Bavarian Nordic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-25T10:36:43Z,2021-10-25T10:36:43Z,81
NCT05075083,NA,2021-10-04,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z,75
NCT05075070,NA,2021-10-05,NA,NA,2021-10-21,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z,74
NCT05075057,NA,2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:47Z,2021-10-25T10:36:47Z,75
NCT05075044,NA,2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged â‰¥18 Years With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥18 Years With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:48Z,2021-10-25T10:36:48Z,75
NCT05091411,NA,2021-10-12,NA,NA,2021-10-12,2021-10-12,2021-10-25,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-25,Estimate,"September 9, 2021",Actual,2021-09-09,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),"Randomized, Double-blind, Parallel-controlled Evaluation of the Immunogenicity Consistency and Safety of the Three Batches of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Process Verification in the 18-59-year-old Population, and the Comparison With the Pilot-scale Batch Immunogenicity Non-inferiority Bridging and Safety Clinical Trials",Recruiting,NA,Phase 3,1680,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:28:44Z,2021-10-26T10:28:44Z,83
NCT05069129,NA,2021-10-03,NA,NA,2021-10-17,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-17,2021-10-25,Estimate,"October 14, 2021",Actual,2021-10-14,October 2021,2021-10-31,February 2024,Anticipated,2024-02-29,December 2023,Anticipated,2023-12-31,NA,Interventional,NA,NA,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,NA,Phase 1/Phase 2,1848,Anticipated,"National Vaccine and Serum Institute, China",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:30:22Z,2021-10-26T10:30:22Z,78
NCT05037201,NA,2021-09-07,NA,NA,2021-10-21,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-26,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,"November 8, 2021",Anticipated,2021-11-08,"October 25, 2021",Anticipated,2021-10-25,NA,Interventional,NA,NA,Text Message Nudges for COVID-19 Vaccination,A Randomized Trial of Text Message-Based Nudges to Increase COVID-19 Vaccination,"Active, not recruiting",NA,Not Applicable,2000,Actual,Ascension South East Michigan,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual patient data will not be shared,2021-10-27T12:59:40Z,2021-10-27T12:59:40Z,74
NCT05054621,NA,2021-09-13,NA,NA,2021-10-19,2021-09-22,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-26,Estimate,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",Recruiting,NA,Phase 2,110,Anticipated,Chang Gung Memorial Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:59:21Z,2021-10-27T12:59:21Z,76
NCT04839042,NA,2021-04-07,NA,NA,2021-10-19,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"June 28, 2021",Actual,2021-06-28,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular or Intranasal Administration in Healthy Volunteers",Recruiting,NA,Phase 1,100,Anticipated,Tetherex Pharmaceuticals Corporation,NA,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:08:24Z,2021-10-28T11:08:24Z,76
NCT04960228,NA,2021-06-30,NA,NA,2021-10-26,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 30, 2021",Actual,2021-07-30,October 2021,2021-10-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention,Completed,NA,Not Applicable,1623,Actual,Sir Mortimer B. Davis - Jewish General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Consent form, data collection method, and organizational policy means only aggregated data will be shared with other researchers.",2021-10-28T11:07:01Z,2021-10-28T11:07:01Z,69
NCT04952402,NA,2021-06-28,NA,NA,2021-10-26,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 16, 2021",Actual,2021-07-16,October 2021,2021-10-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,NA,NA,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,Recruiting,NA,Phase 4,700,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-10-28T11:07:03Z,2021-10-28T11:07:03Z,69
NCT05096845,NA,2021-10-21,NA,NA,2021-10-25,2021-10-25,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"August 25, 2021",Actual,2021-08-25,October 2021,2021-10-31,"April 22, 2023",Anticipated,2023-04-22,"March 2, 2023",Anticipated,2023-03-02,NA,Interventional,COVID-19,NA,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,22500,Anticipated,Livzon Pharmaceutical Group Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-28T11:02:20Z,2021-10-28T11:02:20Z,70
NCT05096026,NA,2021-10-25,NA,NA,2021-10-26,2021-10-26,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"March 29, 2021",Actual,2021-03-29,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"May 20, 2021",Actual,2021-05-20,NA,Interventional,NA,NA,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,NA,Not Applicable,8287,Actual,Kaiser Permanente,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"December 1, 2022 through December 1, 2024","Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",NA,Yes,"Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",2021-10-28T11:03:10Z,2021-10-28T11:03:10Z,69
NCT04449276,NA,2020-06-18,NA,NA,2021-10-26,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 18, 2020",Actual,2020-06-18,July 2021,2021-07-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults","Active, not recruiting",NA,Phase 1,280,Actual,CureVac AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:12:04Z,2021-10-28T11:12:04Z,69
NCT05069623,NA,2021-10-04,NA,NA,2021-10-27,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 27, 2021",Anticipated,2021-10-27,October 2021,2021-10-31,October 2023,Anticipated,2023-10-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers,"A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Vaccibody AS,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 25 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-29T11:07:24Z,2021-10-29T11:07:24Z,68
NCT04956224,NA,2021-06-21,NA,NA,2021-10-20,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"August 9, 2021",Actual,2021-08-09,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Immunogenicity of VLA2101 Compared to VLA2001.,"A Randomized, Observer-Blind, Controlled, Non-Inferiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2101 Vaccine To VLA2001 Vaccine, In Volunteers Aged â‰¥12 Years.","Active, not recruiting",NA,Phase 3,900,Anticipated,Valneva Austria GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:09:07Z,2021-10-29T11:09:07Z,75
NCT04773067,NA,2021-02-23,NA,NA,2021-10-20,2021-02-24,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"January 30, 2021",Actual,2021-01-30,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 27, 2021",Actual,2021-06-27,NA,Interventional,NA,NA,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers",Recruiting,NA,Phase 2,3850,Anticipated,"United Biomedical Inc., Asia",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:11:04Z,2021-10-29T11:11:04Z,75
NCT04756271,NA,2021-02-13,NA,NA,2021-10-21,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"February 11, 2021",Actual,2021-02-11,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,Recruiting,NA,Phase 3,140,Anticipated,Zagazig University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:11:10Z,2021-10-29T11:11:10Z,74
NCT04992208,NA,2021-08-02,NA,NA,2021-10-28,2021-08-04,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"July 24, 2021",Actual,2021-07-24,August 2021,2021-08-31,"December 25, 2022",Anticipated,2022-12-25,"February 25, 2022",Anticipated,2022-02-25,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study",Recruiting,NA,Phase 4,33000,Anticipated,"Sinovac Biotech Co., Ltd",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:43:00Z,2021-11-01T10:43:00Z,67
NCT04864561,NA,2021-04-23,NA,NA,2021-10-25,2021-04-24,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-29,Estimate,"April 26, 2021",Actual,2021-04-26,October 2021,2021-10-31,"March 16, 2023",Anticipated,2023-03-16,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,COV-COMPARE,NA,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine","A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (â‰¥12 to <18 Years)",Recruiting,NA,Phase 3,4679,Anticipated,Valneva Austria GmbH,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:44:08Z,2021-11-01T10:44:08Z,70
NCT04671017,NA,2020-12-15,NA,NA,2021-10-21,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-29,Estimate,"December 16, 2020",Actual,2020-12-16,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,NA,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,153,Actual,Valneva Austria GmbH,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:45:15Z,2021-11-01T10:45:15Z,74
NCT05099497,NA,2021-10-05,NA,NA,2021-10-18,2021-10-18,2021-10-29,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-29,Estimate,"September 21, 2021",Actual,2021-09-21,October 2021,2021-10-31,"September 1, 2022",Anticipated,2022-09-01,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,Supporting Audit and Feedback to Encourage Vaccine Uptake,Big Data and Little Behaviours: Feedback and Quality Improvement Supports to Primary Care to Facilitate COVID Vaccine Uptake,"Active, not recruiting",NA,Not Applicable,600,Actual,Women's College Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data analysis will take place at the Institute for Clinical Evaluative Sciences (ICES). Ontario Health will provide ICES with a list of physicians that were in either the control or intervention group. This list will be transferred to ICES using a secure portal process (axway). Data will be captured from administrative databases (including COVaxON registry data) held at ICES. Data will be linked at the physician level using their encrypted CPSO (College of Physicians and Surgeons of Ontario) number.,2021-11-01T10:40:51Z,2021-11-01T10:40:51Z,77
NCT04911790,NA,2021-06-02,NA,NA,2021-10-28,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"June 5, 2021",Actual,2021-06-05,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"October 5, 2021",Actual,2021-10-05,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 18 Years and Older: A Multicenter,Open-label Study",Recruiting,NA,Phase 4,121000,Anticipated,"Sinovac Biotech Co., Ltd",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-01T10:43:45Z,2021-11-01T10:43:45Z,67
NCT04505774,NA,2020-08-06,NA,NA,2021-10-27,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-29,Estimate,"September 4, 2020",Actual,2020-09-04,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Interventional,ACTIV-4A,NA,Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE,"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 4,3000,Anticipated,University of Pittsburgh,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Data will be shared as per NIH guidelines.,2021-11-01T10:46:34Z,2021-11-01T10:46:34Z,68
NCT04927065,NA,2021-06-14,NA,NA,2021-10-25,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"May 28, 2021",Actual,2021-05-28,October 2021,2021-10-31,"November 30, 2022",Anticipated,2022-11-30,"June 16, 2022",Anticipated,2022-06-16,NA,Interventional,NA,NA,A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants,A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants,Recruiting,NA,Phase 2/Phase 3,3620,Anticipated,"ModernaTX, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:30:48Z,2021-11-02T11:30:48Z,70
NCT04642638,NA,2020-11-23,NA,NA,2021-10-29,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,NA,NA,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,NA,Phase 2/Phase 3,7517,Anticipated,Inovio Pharmaceuticals,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-03T11:07:47Z,2021-11-03T11:07:47Z,66
NCT05107375,NA,2021-11-01,NA,NA,2021-11-03,2021-11-03,2021-11-04,Estimate,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"September 3, 2021",Actual,2021-09-03,November 2021,2021-11-30,"March 4, 2022",Anticipated,2022-03-04,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell) Combined With Influenza Vaccine,Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and Over,Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:03:28Z,2021-11-05T12:03:28Z,61
NCT04951388,NA,2021-06-30,NA,NA,2021-11-02,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"July 22, 2021",Actual,2021-07-22,August 2021,2021-08-31,May 2022,Anticipated,2022-05-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:57Z,2021-11-05T12:06:57Z,62
NCT05048849,NA,2021-09-03,NA,NA,2021-11-02,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"July 19, 2021",Actual,2021-07-19,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study","Active, not recruiting",NA,Phase 2,274,Actual,Medigen Vaccine Biologics Corp.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:36Z,2021-11-05T12:05:36Z,62
NCT05038618,NA,2021-08-25,NA,NA,2021-11-02,2021-08-31,2021-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"August 2, 2021",Actual,2021-08-02,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:47Z,2021-11-05T12:05:47Z,62
NCT04977024,NA,2021-06-11,NA,NA,2021-11-02,2021-07-22,2021-07-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"September 27, 2021",Actual,2021-09-27,November 2021,2021-11-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2023",Anticipated,2023-06-01,NA,Interventional,NA,NA,SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,"A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)",Recruiting,NA,Phase 2,240,Anticipated,City of Hope Medical Center,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:38Z,2021-11-05T12:06:38Z,62
NCT04822025,NA,2021-03-25,NA,NA,2021-11-02,2021-03-28,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults","Active, not recruiting",NA,Phase 2,420,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:05Z,2021-11-05T12:08:05Z,62
NCT04695652,NA,2020-12-31,NA,NA,2021-11-02,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"December 30, 2020",Actual,2020-12-30,December 2020,2020-12-31,June 2022,Anticipated,2022-06-30,"June 2, 2021",Actual,2021-06-02,NA,Interventional,COVID-19,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901","Active, not recruiting",NA,Phase 2,3854,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:09:32Z,2021-11-05T12:09:32Z,62
NCT04953078,NA,2021-06-14,NA,NA,2021-10-29,2021-07-06,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-05,Estimate,"September 11, 2021",Actual,2021-09-11,October 2021,2021-10-31,February 2023,Anticipated,2023-02-28,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19","A Phase 1, Randomized, Open-label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Reactogenicity of Escalating Doses of the Baiya SARS-CoV-2 Vax 1 Vaccine in Healthy Adults",Recruiting,NA,Phase 1,96,Anticipated,"Baiya Phytopharm Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:35Z,2021-11-08T11:22:35Z,66
NCT04569383,NA,2020-09-21,NA,NA,2021-11-04,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"October 5, 2020",Actual,2020-10-05,November 2021,2021-11-30,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",Completed,NA,Phase 1,30,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:01Z,2021-11-08T11:26:01Z,60
NCT04460703,NA,2020-07-02,NA,NA,2021-10-28,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"July 3, 2020",Actual,2020-07-03,October 2021,2021-10-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,NA,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,Not Applicable,4000,Actual,Yale University,NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-11-08T11:26:40Z,2021-11-08T11:26:40Z,67
NCT05113849,NA,2021-10-29,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"September 16, 2021",Actual,2021-09-16,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,February 2023,Anticipated,2023-02-28,NA,Interventional,NA,NA,Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19),"A Phase 1, Open-label, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults Aged at 19 to 55 Years",Recruiting,NA,Phase 1,40,Anticipated,HK inno.N Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:54Z,2021-11-10T21:58:54Z,56
NCT04523571,NA,2020-08-18,NA,NA,2021-11-05,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-11,Estimate,"July 28, 2020",Actual,2020-07-28,November 2021,2021-11-30,"August 10, 2021",Actual,2021-08-10,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Completed,NA,Phase 1,144,Actual,BioNTech SE,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:12Z,2021-11-11T21:28:12Z,59
NCT05046548,NA,2021-08-26,NA,NA,2021-11-11,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"October 3, 2020",Actual,2020-10-03,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years",Completed,NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:24:34Z,2021-11-15T12:24:34Z,53
NCT05037097,NA,2021-08-30,NA,NA,2021-11-10,2021-09-03,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"August 30, 2021",Actual,2021-08-30,November 2021,2021-11-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,"A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,"Arcturus Therapeutics, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-11-15T12:24:40Z,2021-11-15T12:24:40Z,54
NCT04969601,NA,2021-07-19,NA,NA,2021-11-08,2021-07-19,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-15,Estimate,"September 29, 2021",Actual,2021-09-29,November 2021,2021-11-30,"March 29, 2023",Anticipated,2023-03-29,"May 29, 2022",Anticipated,2022-05-29,NA,Interventional,PACIFIC,NA,Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings,Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (â‰¥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity.,Recruiting,NA,Phase 1/Phase 2,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-16T00:50:19Z,2021-11-16T00:50:19Z,56
NCT04816019,NA,2021-03-15,NA,NA,2021-11-12,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Recruiting,NA,Phase 1,54,Anticipated,University of Oxford,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:51:55Z,2021-11-16T00:51:55Z,52
NCT05113862,NA,2021-11-05,NA,NA,2021-11-09,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,December 2021,Anticipated,2021-12-31,November 2021,2021-11-30,November 2022,Anticipated,2022-11-30,October 2022,Anticipated,2022-10-31,NA,Interventional,naNO-COVID,NA,Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19,"A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against Coronavirus COVID-19 in Healthy Adults in Switzerland",Recruiting,NA,Phase 1,26,Anticipated,Emergex Vaccines Holding Ltd.,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of study completion,Peer-reviewed publication,NA,Yes,"The Investigators will be involved in writing and /or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.

Apart from the obvious flaws to conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorisation of the PI and Sponsor.

Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.",2021-11-18T11:24:04Z,2021-11-18T11:24:04Z,55
NCT04870593,NA,2021-04-28,NA,NA,2021-11-16,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"April 17, 2021",Actual,2021-04-17,November 2021,2021-11-30,"July 10, 2023",Anticipated,2023-07-10,"July 10, 2023",Anticipated,2023-07-10,NA,Interventional,NA,NA,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",NA,Not Applicable,3006,Actual,"National Bureau of Economic Research, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:27:46Z,2021-11-18T11:27:46Z,48
NCT05125874,NA,2021-11-09,NA,NA,2021-11-14,2021-11-14,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-18,Actual,"September 30, 2021",Actual,2021-09-30,November 2021,2021-11-30,"September 30, 2023",Anticipated,2023-09-30,"August 30, 2023",Anticipated,2023-08-30,NA,Interventional,COVID-19,NA,Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization,A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines,"Active, not recruiting",NA,Not Applicable,45,Actual,Livzon Pharmaceutical Group Inc.,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:43Z,2021-11-19T20:22:43Z,50
NCT04847102,NA,2021-04-13,NA,NA,2021-11-10,2021-04-13,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"July 22, 2021",Actual,2021-07-22,November 2021,2021-11-30,"May 30, 2023",Anticipated,2023-05-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above,"A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older",Recruiting,NA,Phase 3,28000,Anticipated,"Walvax Biotechnology Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:30:24Z,2021-11-19T20:30:24Z,54
NCT05049226,NA,2021-09-14,NA,NA,2021-11-11,2021-09-16,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-19,Estimate,"September 24, 2021",Actual,2021-09-24,November 2021,2021-11-30,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine,"A Randomized, Observer-blind Trial to Assess the Immunogenicity and Safety of Third Dose Vaccination With AstraZeneca COVID-19 Vaccine or Pfizer/BioNTech COVID-19 Vaccine Among Thai Adults Receiving Two Doses of Sinovac",Enrolling by invitation,NA,Phase 2,1320,Anticipated,Mahidol University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,2 years,as document attach when completed study in NCT clinicaltrials.gov,NA,Yes,data or left over specimen will be shared for future study ONLY subject who consent allow using their data/specimens. Sharing will be done without personnel identification,2021-11-19T20:26:51Z,2021-11-19T20:26:51Z,53
NCT05047718,NA,2021-09-14,NA,NA,2021-11-17,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"October 5, 2021",Actual,2021-10-05,November 2021,2021-11-30,"March 3, 2023",Anticipated,2023-03-03,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,COVIMMUNAGE,NA,Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19,Factors Influencing the COVID-19 Vaccine Immune Response (Reactogenicity and Immunogenicity) According to Age and Presence or Not of a Past History of COVID-19,Recruiting,NA,Phase 4,200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:26:54Z,2021-11-19T20:26:54Z,47
NCT04869358,NA,2021-04-29,NA,NA,2021-11-10,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"May 27, 2021",Actual,2021-05-27,November 2021,2021-11-30,"May 31, 2023",Anticipated,2023-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,KYRIOS,NA,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS),Recruiting,NA,Phase 4,40,Anticipated,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-11-19T20:30:04Z,2021-11-19T20:30:04Z,54
NCT04800133,NA,2021-03-01,NA,NA,2021-11-10,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"May 8, 2021",Actual,2021-05-08,November 2021,2021-11-30,"March 31, 2025",Anticipated,2025-03-31,"March 31, 2025",Anticipated,2025-03-31,NA,Interventional,COVAC,NA,Covid-19 Vaccination in Adolescents and Children,To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong Kong,Recruiting,NA,Phase 2,1000,Anticipated,The University of Hong Kong,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:31:12Z,2021-11-19T20:31:12Z,54
NCT04798027,NA,2021-03-11,NA,NA,2021-11-18,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"March 12, 2021",Actual,2021-03-12,"November 18, 2021",2021-11-18,"November 2, 2022",Anticipated,2022-11-02,"November 2, 2022",Anticipated,2022-11-02,NA,Interventional,VAW00001,NA,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",NA,Phase 1/Phase 2,182,Actual,Sanofi,NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-19T20:31:15Z,2021-11-19T20:31:15Z,46
NCT04336410,NA,2020-04-03,NA,NA,2021-11-18,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"April 3, 2020",Actual,2020-04-03,November 2021,2021-11-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-19T20:37:08Z,2021-11-19T20:37:08Z,46
NCT04327206,NA,2020-03-25,NA,NA,2021-11-10,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"March 30, 2020",Actual,2020-03-30,November 2021,2021-11-30,"March 30, 2022",Anticipated,2022-03-30,"November 20, 2021",Anticipated,2021-11-20,NA,Interventional,BRACE,NA,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,"Active, not recruiting",NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:

Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2021-11-19T20:37:16Z,2021-11-19T20:37:16Z,54
NCT05128721,NA,2021-11-12,NA,NA,2021-11-18,2021-11-18,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"November 14, 2021",Actual,2021-11-14,November 2021,2021-11-30,"May 23, 2023",Anticipated,2023-05-23,"February 23, 2023",Anticipated,2023-02-23,NA,Interventional,NA,NA,Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19),"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults",Recruiting,NA,Phase 1,72,Anticipated,"National Research Centre, Egypt",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,About one year after completion of the trial,Data will be shared upon individual request by contacting the sponsor of the trial.,NA,Yes,Data will be shared upon individual request.,2021-11-23T11:37:12Z,2021-11-23T11:37:12Z,46
NCT05128643,NA,2021-11-18,NA,NA,2021-11-18,2021-11-18,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"September 17, 2021",Actual,2021-09-17,November 2021,2021-11-30,"October 12, 2022",Anticipated,2022-10-12,"April 12, 2022",Anticipated,2022-04-12,NA,Interventional,NA,NA,Clinical Study on the Immune Program of Recombinant Novel Coronavirusï¼ˆCOVID-19) Vaccine (CHO Cell),"Clinical Study on the Immunogenicity and Safety of the Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) 0, 1, and 6 Months Immunization Program in People 18 Years of Age and Older",Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:37:15Z,2021-11-23T11:37:15Z,46
NCT04839146,NA,2021-03-11,NA,NA,2021-11-18,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"March 11, 2021",Actual,2021-03-11,March 2021,2021-03-31,"December 20, 2021",Anticipated,2021-12-20,"December 20, 2021",Anticipated,2021-12-20,NA,Interventional,COUGH-1,NA,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naÃ¯ve Adult Volunteers in Good Health,"Active, not recruiting",NA,Phase 1,45,Actual,Radboud University,NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:41:46Z,2021-11-23T11:41:46Z,46
NCT05109598,NA,2021-11-04,NA,NA,2021-11-14,2021-11-04,2021-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-22,Estimate,"November 4, 2021",Actual,2021-11-04,November 2021,2021-11-30,March 2023,Anticipated,2023-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell),A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.,Recruiting,NA,Phase 2,400,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:38:11Z,2021-11-23T11:38:11Z,50
NCT05107557,NA,2021-11-02,NA,NA,2021-11-22,2021-11-02,2021-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"November 5, 2021",Actual,2021-11-05,November 2021,2021-11-30,"May 5, 2022",Anticipated,2022-05-05,"December 5, 2021",Anticipated,2021-12-05,NA,Interventional,NA,NA,"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","A Randomized and Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old",Recruiting,NA,Phase 4,520,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:54:58Z,2021-11-24T09:54:58Z,42
NCT04954287,NA,2021-06-30,NA,NA,2021-11-15,2021-06-30,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"August 6, 2021",Actual,2021-08-06,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,March 2022,Anticipated,2022-03-31,NA,Interventional,CVXGA1-001,NA,Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of Intranasal Parainfluenza Virus Type 5-SARS-CoV-2 S Vaccine (CVXGA1) in Healthy Adults Aged 18 to 75 Years",Recruiting,NA,Phase 1,80,Anticipated,CyanVac LLC,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"5 years, beginning as soon as possible (but no later than 12 months) after article publication",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,NA,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2021-11-24T09:57:22Z,2021-11-24T09:57:22Z,49
NCT05028361,NA,2021-08-30,NA,NA,2021-11-15,2021-08-30,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"October 4, 2021",Actual,2021-10-04,November 2021,2021-11-30,"July 14, 2022",Anticipated,2022-07-14,"April 5, 2022",Anticipated,2022-04-05,NA,Interventional,NA,NA,Simultaneous mRNA COVID-19 and IIV4 Vaccination Study,Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza Vaccine (IIV4) in Adults and Adolescents: A Randomized Observer Blinded Study,Recruiting,NA,Phase 4,450,Anticipated,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:56:36Z,2021-11-24T09:56:36Z,49
NCT05022329,NA,2021-08-23,NA,NA,2021-11-22,2021-08-25,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"September 30, 2021",Actual,2021-09-30,November 2021,2021-11-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,BOOST KIDNEY,NA,COVID-19 Vaccine Boosters in Patients With CKD,A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sunnybrook Health Sciences Centre,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T09:56:43Z,2021-11-24T09:56:43Z,42
NCT05133609,NA,2021-11-01,NA,NA,2021-11-23,2021-11-23,2021-11-24,Estimate,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"January 15, 2021",Actual,2021-01-15,November 2021,2021-11-30,"December 30, 2023",Anticipated,2023-12-30,"August 1, 2022",Anticipated,2022-08-01,NA,Interventional,NA,NA,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,Recruiting,NA,Phase 1/Phase 2,550,Anticipated,Federal University of Espirito Santo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:06:59Z,2021-11-25T10:06:59Z,41
NCT05037266,NA,2021-09-06,NA,NA,2021-11-23,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"September 20, 2021",Actual,2021-09-20,September 2021,2021-09-30,"April 30, 2024",Anticipated,2024-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,CoviCompare_J,NA,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Recruiting,NA,Phase 4,120,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:10:32Z,2021-11-25T10:10:32Z,41
NCT04754594,NA,2021-02-09,NA,NA,2021-11-16,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"February 16, 2021",Actual,2021-02-16,November 2021,2021-11-30,"August 24, 2022",Anticipated,2022-08-24,"August 24, 2022",Anticipated,2022-08-24,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER","Active, not recruiting",NA,Phase 2/Phase 3,343,Actual,BioNTech SE,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-25T10:13:45Z,2021-11-25T10:13:45Z,48
NCT04445428,NA,2020-06-22,NA,NA,2021-11-16,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"July 15, 2020",Actual,2020-07-15,November 2021,2021-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,"Active, not recruiting",NA,Phase 4,3400,Anticipated,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Provided request, data can be made available",2021-11-25T10:15:37Z,2021-11-25T10:15:37Z,48
NCT05069649,NA,2021-10-04,NA,NA,2021-11-25,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"October 6, 2021",Actual,2021-10-06,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2,"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,3600,Anticipated,Materia Medica Holding,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:33Z,2021-11-30T11:20:33Z,39
NCT04867174,NA,2021-04-27,NA,NA,2021-11-16,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-26,Actual,"May 24, 2021",Actual,2021-05-24,November 2021,2021-11-30,"May 24, 2022",Anticipated,2022-05-24,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,COVID-19 Vaccination Take-Up,COVID-19 Vaccination Take-Up in a County-Run Medicaid Managed Care Population,"Active, not recruiting",NA,Not Applicable,2825,Actual,University of Southern California,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Our partner will not allow data sharing. Code will be shared.,2021-11-30T11:24:25Z,2021-11-30T11:24:25Z,48
NCT04904549,NA,2021-05-26,NA,NA,2021-11-25,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"May 26, 2021",Actual,2021-05-26,"November 25, 2021",2021-11-25,"March 8, 2023",Anticipated,2023-03-08,"March 8, 2023",Anticipated,2023-03-08,NA,Interventional,VAT00008,NA,Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older,"A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,21046,Anticipated,Sanofi,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-30T11:23:48Z,2021-11-30T11:23:48Z,39
NCT04639466,NA,2020-11-04,NA,NA,2021-11-23,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-26,Actual,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"November 10, 2022",Anticipated,2022-11-10,"November 10, 2022",Anticipated,2022-11-10,NA,Interventional,NA,NA,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19","Phase 1 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections to Healthy Adult Volunteers",Recruiting,NA,Phase 1,129,Anticipated,City of Hope Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:19Z,2021-11-30T11:27:19Z,41
NCT04979949,NA,2021-07-15,NA,NA,2021-11-17,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-30,Estimate,"July 12, 2021",Actual,2021-07-12,November 2021,2021-11-30,"March 11, 2022",Anticipated,2022-03-11,"March 11, 2022",Anticipated,2022-03-11,NA,Interventional,NA,NA,Booster Vaccination Against COVID-19,"Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2","Active, not recruiting",NA,Phase 2,222,Actual,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:27:29Z,2021-12-01T10:27:29Z,47
NCT04878211,NA,2021-05-03,NA,NA,2021-11-28,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-28,2021-11-30,Estimate,"June 10, 2021",Actual,2021-06-10,November 2021,2021-11-30,"November 18, 2022",Anticipated,2022-11-18,"November 26, 2021",Anticipated,2021-11-26,NA,Interventional,NA,NA,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,Recruiting,NA,Phase 4,66,Anticipated,Novartis,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-12-01T10:29:13Z,2021-12-01T10:29:13Z,36
NCT04895449,NA,2021-04-24,NA,NA,2021-11-23,2021-05-15,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-30,Estimate,"July 16, 2021",Actual,2021-07-16,November 2021,2021-11-30,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,MVA-SARS2-ST,NA,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","A Multi-center Phase Ib Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",Recruiting,NA,Phase 1,60,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:28:55Z,2021-12-01T10:28:55Z,41
NCT04568031,NA,2020-08-21,NA,NA,2021-11-29,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-29,2021-11-30,Estimate,"August 23, 2020",Actual,2020-08-23,November 2021,2021-11-30,"November 22, 2021",Actual,2021-11-22,"November 22, 2021",Actual,2021-11-22,NA,Interventional,NA,NA,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Completed,NA,Phase 1/Phase 2,256,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-01T10:32:40Z,2021-12-01T10:32:40Z,35
NCT04405076,NA,2020-05-13,NA,NA,2021-11-27,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-27,2021-11-30,Estimate,"May 29, 2020",Actual,2020-05-29,November 2021,2021-11-30,"October 26, 2021",Actual,2021-10-26,"October 26, 2021",Actual,2021-10-26,NA,Interventional,NA,NA,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older",Completed,NA,Phase 2,660,Actual,"ModernaTX, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:33:49Z,2021-12-01T10:33:49Z,37
NCT04334980,NA,2020-03-31,NA,NA,2021-11-26,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-30,Estimate,"November 2, 2020",Actual,2020-11-02,November 2021,2021-11-30,"February 28, 2022",Anticipated,2022-02-28,"February 8, 2022",Anticipated,2022-02-08,NA,Interventional,NA,NA,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,24,Anticipated,Symvivo Corporation,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-01T10:34:06Z,2021-12-01T10:34:06Z,38
NCT05069454,NA,2021-06-10,NA,NA,2021-10-05,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"May 10, 2021",Actual,2021-05-10,July 2021,2021-07-31,"July 20, 2022",Anticipated,2022-07-20,"May 20, 2022",Anticipated,2022-05-20,NA,Interventional,VaccEffect,NA,Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Recruiting,NA,Not Applicable,1500,Anticipated,Public health and reforms Center of Ministry of Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T01:37:29Z,2021-12-02T01:37:29Z,90
NCT05060939,NA,2021-09-28,NA,NA,2021-09-28,2021-09-28,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"July 30, 2021",Actual,2021-07-30,September 2021,2021-09-30,"July 30, 2023",Anticipated,2023-07-30,"July 30, 2022",Anticipated,2022-07-30,NA,Interventional,COVID-IVAC,NA,SARS-CoV-2 Infection in COVID-19 Vaccinated Patients,Characterization of the Viral Genome and Humoral Immune Response in COVID-19 Vaccinated Patients With SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,5000,Anticipated,Hospices Civils de Lyon,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:42:38Z,2021-12-02T01:42:38Z,97
NCT05060991,NA,2021-09-24,NA,NA,2021-09-27,2021-09-27,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"September 24, 2021",Actual,2021-09-24,September 2021,2021-09-30,"September 24, 2022",Anticipated,2022-09-24,"December 24, 2021",Anticipated,2021-12-24,NA,Interventional,ADIVKT,NA,Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients,Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT),Recruiting,NA,Phase 4,50,Anticipated,"University of California, Davis",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:42:39Z,2021-12-02T01:42:39Z,98
NCT05059106,NA,2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"October 30, 2022",Anticipated,2022-10-30,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,NA,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",Recruiting,NA,Phase 2/Phase 3,29637,Anticipated,Federal University of Espirito Santo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:43:41Z,2021-12-02T01:43:41Z,101
NCT05057182,NA,2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"September 27, 2021",Anticipated,2021-09-27,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Third Dose of mRNA Vaccination to Boost COVID-19 Immunity,"mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the ""mBoost"" Study)",Recruiting,NA,Phase 4,100,Anticipated,The University of Hong Kong,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T01:45:00Z,2021-12-02T01:45:00Z,101
NCT05050474,NA,2021-09-13,NA,NA,2021-09-13,2021-09-13,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-20,Actual,"August 7, 2021",Actual,2021-08-07,September 2021,2021-09-30,"February 3, 2022",Anticipated,2022-02-03,"August 23, 2021",Actual,2021-08-23,NA,Interventional,NA,NA,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants,"Active, not recruiting",NA,Phase 1,43,Actual,Livzon Pharmaceutical Group Inc.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:49:47Z,2021-12-02T01:49:47Z,112
NCT05047692,NA,2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-17,Actual,"September 9, 2021",Actual,2021-09-09,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.",Recruiting,NA,Phase 1,40,Anticipated,"Cellid Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:51:25Z,2021-12-02T01:51:25Z,111
NCT05043259,NA,2021-09-13,NA,NA,2021-09-15,2021-09-13,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 13, 2021",Actual,2021-09-13,September 2021,2021-09-30,"May 1, 2022",Anticipated,2022-05-01,"October 13, 2021",Anticipated,2021-10-13,NA,Interventional,NA,NA,Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:54:21Z,2021-12-02T01:54:21Z,110
NCT05037188,NA,2021-09-07,NA,NA,2021-09-07,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 10, 2021",Actual,2021-08-10,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,COVER,NA,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),"A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Biocad,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:27Z,2021-12-02T01:58:27Z,118
NCT05033860,NA,2021-08-30,NA,NA,2021-09-01,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-05,Actual,"August 18, 2021",Actual,2021-08-18,August 2021,2021-08-31,"September 20, 2021",Anticipated,2021-09-20,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents: A Randomized Controlled Trial,Recruiting,NA,Not Applicable,312,Anticipated,Ningbo No. 1 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:00:42Z,2021-12-02T02:00:42Z,124
NCT05033158,NA,2021-04-02,NA,NA,2021-08-31,2021-08-31,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-02,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,REAL-V,NA,The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.,Investigation to Reveal the Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population: COVID-19 Protection and Vaccine Safety (REAL-V),Recruiting,NA,Not Applicable,3000,Anticipated,"University Hospital, Antwerp",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:01:13Z,2021-12-02T02:01:13Z,125
NCT05028374,NA,2021-08-23,NA,NA,2021-08-29,2021-08-29,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-08-31,Actual,"August 17, 2021",Actual,2021-08-17,August 2021,2021-08-31,"January 31, 2023",Anticipated,2023-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies,Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination,Recruiting,NA,Phase 2,171,Anticipated,Barbara Ann Karmanos Cancer Institute,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:04:22Z,2021-12-02T02:04:22Z,127
NCT05027672,NA,2021-08-18,NA,NA,2021-08-24,2021-08-24,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"July 30, 2021",Actual,2021-07-30,August 2021,2021-08-31,"September 6, 2021",Anticipated,2021-09-06,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).","Active, not recruiting",NA,Phase 2,348,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:04:49Z,2021-12-02T02:04:49Z,132
NCT05021016,NA,2021-08-19,NA,NA,2021-08-26,2021-08-19,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:09:19Z,2021-12-02T02:09:19Z,130
NCT05018078,NA,2021-08-18,NA,NA,2021-09-01,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"August 30, 2021",Actual,2021-08-30,August 2021,2021-08-31,"June 30, 2023",Anticipated,2023-06-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer,The Fifth Medical Center of Chinese PLA General Hospital,Recruiting,NA,Not Applicable,300,Anticipated,Beijing 302 Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:11:33Z,2021-12-02T02:11:33Z,124
NCT05017805,NA,2021-08-12,NA,NA,2021-09-12,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-12,2021-09-16,Actual,"August 15, 2021",Actual,2021-08-15,August 2021,2021-08-31,"June 15, 2023",Anticipated,2023-06-15,"December 15, 2022",Anticipated,2022-12-15,NA,Interventional,NA,NA,COVID-19 Vaccines in Patients With Chronic Liver Disease,Safety and Immunogenicity of COVID-19 Vaccines in Patients With Chronic Liver Disease: A Multi-center Prospective Study,Recruiting,NA,Not Applicable,300,Anticipated,Beijing 302 Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:11:46Z,2021-12-02T02:11:46Z,113
NCT05017792,NA,2021-08-23,NA,NA,2021-08-29,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"August 30, 2021",Anticipated,2021-08-30,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,NA,"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt","Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt",Recruiting,NA,Phase 3,200,Anticipated,Theodor Bilharz Research Institute,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:11:47Z,2021-12-02T02:11:47Z,127
NCT05012800,NA,2021-08-12,NA,NA,2021-08-18,2021-08-18,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 28, 2021",Actual,2021-07-28,July 2021,2021-07-31,"September 30, 2022",Anticipated,2022-09-30,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults: A Multicenter Prospective Study,Recruiting,NA,Phase 4,300,Anticipated,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T02:15:19Z,2021-12-02T02:15:19Z,138
NCT05007496,NA,2021-08-11,NA,NA,2021-08-16,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:18:52Z,2021-12-02T02:18:52Z,140
NCT05005559,NA,2021-08-11,NA,NA,2021-10-04,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 7, 2021",Actual,2021-08-07,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 3,16876,Anticipated,Cinnagen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:20:18Z,2021-12-02T02:20:18Z,91
NCT05007509,NA,2021-08-12,NA,NA,2021-09-22,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"August 16, 2021",Actual,2021-08-16,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19),A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers,"Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"Laboratorios Hipra, S.A.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,To be decided,2021-12-02T02:18:57Z,2021-12-02T02:18:57Z,103
NCT05005156,NA,2021-06-07,NA,NA,2021-09-14,2021-08-06,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-21,Actual,"June 24, 2021",Actual,2021-06-24,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,COVID-19,NA,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",Recruiting,NA,Phase 2,876,Anticipated,FundaciÃ³n HuÃ©sped,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:20:27Z,2021-12-02T02:20:27Z,111
NCT04996238,NA,2021-07-05,NA,NA,2021-08-05,2021-08-05,2021-08-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"February 11, 2021",Actual,2021-02-11,August 2021,2021-08-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,COVACC2,NA,Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers,COVACC2: Local and General Immune Response After COVID-19 Vaccination in Volunteers,"Active, not recruiting",NA,Not Applicable,300,Anticipated,"University Hospital, Ghent",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:26:51Z,2021-12-02T02:26:51Z,151
NCT04993586,NA,2021-07-30,NA,NA,2021-10-04,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"July 29, 2021",Actual,2021-07-29,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"March 26, 2022",Anticipated,2022-03-26,NA,Interventional,NA,NA,Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose),"A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19","Active, not recruiting",NA,Phase 1/Phase 2,400,Anticipated,"AnGes, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:28:33Z,2021-12-02T02:28:33Z,91
NCT04992182,NA,2021-08-02,NA,NA,2021-08-04,2021-08-04,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"July 8, 2021",Actual,2021-07-08,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,REFUERZO,NA,"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)","Active, not recruiting",NA,Phase 2,534,Actual,Universidad del Desarrollo,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Owing to data privacy regulations, the individual-level data in this study cannot be shared (Law N19.628).",2021-12-02T02:29:55Z,2021-12-02T02:29:55Z,152
NCT04993209,NA,2021-08-03,NA,NA,2021-08-04,2021-08-04,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"July 9, 2021",Actual,2021-07-09,August 2021,2021-08-31,September 2023,Anticipated,2023-09-30,April 2023,Anticipated,2023-04-30,NA,Interventional,ADAPTCOV,NA,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Phase I/II Double-blind, Randomized, Stepwise, Adaptive, Controlled Clinical Trial to Assess the Safety and Immunogenicity of the COVID-19 Vaccine (Recombinant, Inactivated) in Adults, in Brazil - ADAPTCOV.",Recruiting,NA,Phase 1/Phase 2,5394,Anticipated,Butantan Institute,NA,32,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:28:50Z,2021-12-02T02:28:50Z,152
NCT04990544,NA,2021-08-02,NA,NA,2021-08-02,2021-08-02,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"July 31, 2021",Actual,2021-07-31,August 2021,2021-08-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 2,1056,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",NA,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:31:06Z,2021-12-02T02:31:06Z,154
NCT04988048,NA,2021-07-29,NA,NA,2021-09-24,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-29,Actual,"August 3, 2021",Actual,2021-08-03,September 2021,2021-09-30,"February 15, 2022",Anticipated,2022-02-15,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ECEHeVac,NA,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Recruiting,NA,Phase 2,1760,Anticipated,"Ministry of Public Health, Argentina",NA,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:32:55Z,2021-12-02T02:32:55Z,101
NCT04983537,NA,2021-07-28,NA,NA,2021-07-28,2021-07-28,2021-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"July 26, 2021",Actual,2021-07-26,July 2021,2021-07-31,"September 26, 2021",Anticipated,2021-09-26,"September 26, 2021",Anticipated,2021-09-26,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Recruiting,NA,Phase 2,120,Anticipated,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:36:15Z,2021-12-02T02:36:15Z,159
NCT04982068,NA,2021-07-26,NA,NA,2021-07-29,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-03,Actual,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 1,144,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:37:21Z,2021-12-02T02:37:21Z,158
NCT04977479,NA,2021-07-24,NA,NA,2021-09-22,2021-07-24,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"September 8, 2021",Actual,2021-09-08,"September 20, 2021",2021-09-20,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose,"A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",Recruiting,NA,Phase 2,100,Anticipated,National Institutes of Health Clinical Center (CC),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:40:48Z,2021-12-02T02:40:48Z,103
NCT04969263,NA,2021-07-16,NA,NA,2021-10-04,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,October 2022,Anticipated,2022-10-31,November 2021,Anticipated,2021-11-30,NA,Interventional,CPAT,NA,COVID-19 Protection After Transplant Pilot Study,Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses,"Active, not recruiting",NA,Phase 2,81,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-12-02T02:46:37Z,2021-12-02T02:46:37Z,91
NCT04969276,NA,2021-07-16,NA,NA,2021-11-30,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-30,2021-12-01,Estimate,"July 16, 2021",Actual,2021-07-16,"November 30, 2021",2021-11-30,"February 2, 2022",Anticipated,2022-02-02,"February 2, 2022",Anticipated,2022-02-02,NA,Interventional,NA,NA,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,"A Phase II, Open-label Study to Assess the Safety and Immunogenicity of FluzoneÂ® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","Active, not recruiting",NA,Phase 2,306,Actual,Sanofi,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-02T02:46:42Z,2021-12-02T02:46:42Z,34
NCT04967807,NA,2021-06-29,NA,NA,2021-08-09,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-16,Actual,"August 5, 2021",Actual,2021-08-05,June 2021,2021-06-30,"June 14, 2022",Anticipated,2022-06-14,"June 14, 2022",Anticipated,2022-06-14,NA,Interventional,MYOVAX,NA,Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Recruiting,NA,Not Applicable,80,Anticipated,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:47:54Z,2021-12-02T02:47:54Z,147
NCT04962308,NA,2021-07-13,NA,NA,2021-09-22,2021-07-13,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"June 19, 2021",Actual,2021-06-19,June 2021,2021-06-30,"December 19, 2021",Anticipated,2021-12-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"An Open-label,Phase â…£ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.",Recruiting,NA,Phase 4,1400,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:52:04Z,2021-12-02T02:52:04Z,103
NCT04964154,NA,2021-07-13,NA,NA,2021-07-13,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-15,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,BRAVE,NA,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Recruiting,NA,Not Applicable,4000,Anticipated,North Carolina Central University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:50:40Z,2021-12-02T02:50:40Z,174
NCT04962906,NA,2021-07-08,NA,NA,2021-08-18,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:51:35Z,2021-12-02T02:51:35Z,138
NCT04962893,NA,2021-07-12,NA,NA,2021-10-04,2021-07-14,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"June 26, 2021",Actual,2021-06-26,July 2021,2021-07-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",Recruiting,NA,Phase 2,330,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:51:40Z,2021-12-02T02:51:40Z,91
NCT04961359,NA,2021-07-08,NA,NA,2021-07-19,2021-07-08,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-23,Actual,"July 3, 2021",Actual,2021-07-03,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase â…  Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Recruiting,NA,Phase 1,75,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:52:35Z,2021-12-02T02:52:35Z,168
NCT04961502,NA,2021-06-04,NA,NA,2021-07-12,2021-07-12,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,COGEVAX-BIO,NA,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Recruiting,NA,Not Applicable,80,Anticipated,GÃ©rond'if,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:52:44Z,2021-12-02T02:52:44Z,175
NCT04954469,NA,2021-07-05,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 30, 2021",Actual,2021-06-30,July 2021,2021-07-31,"March 31, 2022",Anticipated,2022-03-31,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,B-pVAC,NA,B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,Recruiting,NA,Phase 1/Phase 2,68,Anticipated,University Hospital Tuebingen,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:57:51Z,2021-12-02T02:57:51Z,180
NCT04954092,NA,2021-07-05,NA,NA,2021-09-08,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-16,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"November 6, 2022",Anticipated,2022-11-06,NA,Interventional,OLSTAD,NA,Study of Gam-COVID-Vac in Adolescents,"An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus"", With the Participation of Adolescent Volunteers",Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:57:53Z,2021-12-02T02:57:53Z,117
NCT04953325,NA,2021-07-05,NA,NA,2021-07-25,2021-07-05,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-25,2021-07-27,Actual,"July 9, 2021",Actual,2021-07-09,July 2021,2021-07-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older,Recruiting,NA,Phase 4,270,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:58:29Z,2021-12-02T02:58:29Z,162
NCT04952766,NA,2021-06-16,NA,NA,2021-07-07,2021-07-06,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-13,Actual,"March 29, 2021",Actual,2021-03-29,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,EREVA,NA,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Recruiting,NA,Phase 4,240,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:58:52Z,2021-12-02T02:58:52Z,180
NCT04952727,NA,2021-07-03,NA,NA,2021-09-23,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"August 26, 2021",Actual,2021-08-26,July 2021,2021-07-31,"May 26, 2022",Anticipated,2022-05-26,"November 26, 2021",Anticipated,2021-11-26,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults,"Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:58:46Z,2021-12-02T02:58:46Z,102
NCT04944368,NA,2021-06-19,NA,NA,2021-10-04,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Actual,"May 30, 2021",Actual,2021-05-30,October 2021,2021-10-31,"December 15, 2021",Anticipated,2021-12-15,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,NA,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 2,400,Actual,Cinnagen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:05:19Z,2021-12-02T03:05:19Z,91
NCT04939519,NA,2021-04-07,NA,NA,2021-08-10,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-12,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,"September 22, 2022",Anticipated,2022-09-22,"September 22, 2022",Anticipated,2022-09-22,NA,Interventional,NA,NA,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,Not Applicable,110270,Actual,University of Utah,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:08:57Z,2021-12-02T03:08:57Z,146
NCT04939402,NA,2021-04-22,NA,NA,2021-06-24,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-25,Actual,"May 5, 2021",Actual,2021-05-05,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,Recruiting,NA,Not Applicable,200,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:09:09Z,2021-12-02T03:09:09Z,193
NCT04935528,NA,2021-06-18,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"June 2, 2021",Actual,2021-06-02,June 2021,2021-06-30,"June 2, 2022",Anticipated,2022-06-02,"June 2, 2022",Anticipated,2022-06-02,NA,Interventional,CANSEROVAX,NA,Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Recruiting,NA,Not Applicable,430,Anticipated,Centre Georges Francois Leclerc,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:11:45Z,2021-12-02T03:11:45Z,195
NCT04932824,NA,2021-04-13,NA,NA,2021-06-17,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"January 19, 2021",Actual,2021-01-19,April 2021,2021-04-30,"September 14, 2023",Anticipated,2023-09-14,"May 31, 2023",Anticipated,2023-05-31,NA,Interventional,NA,NA,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:14:04Z,2021-12-02T03:14:04Z,200
NCT04930003,NA,2021-02-22,NA,NA,2021-07-22,2021-06-15,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-29,Actual,"June 15, 2021",Actual,2021-06-15,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder","Active, not recruiting",NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:16:15Z,2021-12-02T03:16:15Z,165
NCT04928456,NA,2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-16,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"December 30, 2022",Anticipated,2022-12-30,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,NA,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through Osteopathic Manipulative Treatment Including Lymphatic Pumps,Recruiting,NA,Not Applicable,200,Anticipated,Western University of Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:17:11Z,2021-12-02T03:17:11Z,203
NCT04922788,NA,2021-06-08,NA,NA,2021-06-10,2021-06-10,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-11,Actual,"June 7, 2021",Actual,2021-06-07,June 2021,2021-06-30,"August 7, 2022",Anticipated,2022-08-07,"July 7, 2022",Anticipated,2022-07-07,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19","a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.",Recruiting,NA,Phase 3,13000,Anticipated,Nanogen Pharmaceutical Biotechnology Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:22:01Z,2021-12-02T03:22:01Z,207
NCT04918940,NA,2021-06-04,NA,NA,2021-06-07,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"May 21, 2022",Anticipated,2022-05-21,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,VAXIMAB,NA,Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma,Post-vaccination Immunization Against SARS-CoV-2 in Patients Undergoing Maintenance With Anti-CD20 Antibodies for Follicular Lymphoma (FL) or Mantle Cell,Recruiting,NA,Not Applicable,40,Anticipated,Centre Henri Becquerel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:29:42Z,2021-12-02T03:29:42Z,210
NCT04918797,NA,2021-05-18,NA,NA,2021-07-01,2021-06-02,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"January 25, 2022",Anticipated,2022-01-25,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,COVAXIN-Peds,NA,COVAXIN in a Pediatric Cohort,"A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXINÂ®) in Healthy Volunteers Ages â‰¤18 to â‰¥ 2 Years.",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,Bharat Biotech International Limited,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:31:56Z,2021-12-02T03:31:56Z,186
NCT04916886,NA,2021-05-30,NA,NA,2021-06-04,2021-06-04,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-08,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,August 2022,Anticipated,2022-08-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.,To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.,Recruiting,NA,Not Applicable,2016,Anticipated,CanSino Biologics Inc.,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:34:37Z,2021-12-02T03:34:37Z,213
NCT04915820,NA,2021-05-28,NA,NA,2021-09-10,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 29, 2021",Actual,2021-05-29,September 2021,2021-09-30,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Interventional,NA,NA,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,Not Applicable,121,Actual,Jomo Kenyatta University of Agriculture and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:35:56Z,2021-12-02T03:35:56Z,115
NCT04915989,NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"February 16, 2021",Actual,2021-02-16,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","Active, not recruiting",NA,Phase 1,30,Actual,"Genexine, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:35:37Z,2021-12-02T03:35:37Z,213
NCT04907331,NA,2021-05-25,NA,NA,2021-09-09,2021-05-25,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"May 10, 2021",Actual,2021-05-10,May 2021,2021-05-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,HeVacc,NA,Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2,Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination,Recruiting,NA,Phase 2,3000,Anticipated,Medical University Innsbruck,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:45:50Z,2021-12-02T03:45:50Z,116
NCT04900467,NA,2021-05-21,NA,NA,2021-07-31,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"May 28, 2021",Actual,2021-05-28,July 2021,2021-07-31,January 2022,Anticipated,2022-01-31,"July 2, 2021",Actual,2021-07-02,NA,Interventional,ARNCOMBI,NA,Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine,"Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial","Active, not recruiting",NA,Not Applicable,418,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:54:52Z,2021-12-02T03:54:52Z,156
NCT04896788,NA,2021-05-18,NA,NA,2021-05-21,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"May 19, 2021",Actual,2021-05-19,May 2021,2021-05-31,"May 1, 2024",Anticipated,2024-05-01,"November 1, 2023",Anticipated,2023-11-01,NA,Interventional,COVIDIM,NA,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Recruiting,NA,Not Applicable,300,Anticipated,"University Hospital, Clermont-Ferrand",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:58:36Z,2021-12-02T03:58:36Z,227
NCT04894435,NA,2021-05-18,NA,NA,2021-08-19,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"May 20, 2021",Actual,2021-05-20,August 2021,2021-08-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,MOSAIC,NA,Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity,Immunogenicity and Adverse Events Following Immunization With Alternate Schedules of Authorized COVID-19 Vaccines in Canada: MOSAIC Study (Mix and Match of the Second cOvid-19 Vaccine Dose for SAfety and ImmunogeniCity),Recruiting,NA,Phase 2,1200,Anticipated,Canadian Immunization Research Network,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:00:24Z,2021-12-02T04:00:24Z,137
NCT04894227,NA,2021-05-10,NA,NA,2021-08-16,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 11, 2021",Actual,2021-05-11,May 2021,2021-05-31,"November 30, 2021",Anticipated,2021-11-30,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰ in Health Adults Aged 26-45 Years","Active, not recruiting",NA,Phase 4,1080,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:00:42Z,2021-12-02T04:00:42Z,140
NCT04892459,NA,2021-05-10,NA,NA,2021-06-29,2021-05-16,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"December 25, 2021",Anticipated,2021-12-25,"July 25, 2021",Anticipated,2021-07-25,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector),"Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial","Active, not recruiting",NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:02:41Z,2021-12-02T04:02:41Z,188
NCT04889274,NA,2021-05-06,NA,NA,2021-05-14,2021-05-14,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 10, 2021",Actual,2021-05-10,May 2021,2021-05-31,"May 10, 2022",Anticipated,2022-05-10,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,NA,Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19),"A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women",Recruiting,NA,Phase 1,98,Anticipated,Queen Mary University of London,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:06:10Z,2021-12-02T04:06:10Z,234
NCT04885907,NA,2021-05-09,NA,NA,2021-06-03,2021-05-09,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients,"A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients","Active, not recruiting",NA,Phase 4,120,Actual,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:09:02Z,2021-12-02T04:09:02Z,214
NCT04885764,NA,2021-05-08,NA,NA,2021-05-08,2021-05-08,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-08,2021-05-13,Actual,"February 23, 2021",Actual,2021-02-23,May 2021,2021-05-31,"December 1, 2021",Anticipated,2021-12-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ASU-VAC,NA,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:09:06Z,2021-12-02T04:09:06Z,240
NCT04885361,NA,2021-05-07,NA,NA,2021-06-08,2021-05-12,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"May 26, 2021",Actual,2021-05-26,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COVEPIT 3,NA,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults","A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)",Recruiting,NA,Phase 1,48,Anticipated,OSE Immunotherapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:09:33Z,2021-12-02T04:09:33Z,209
NCT04884685,NA,2021-05-07,NA,NA,2021-09-22,2021-05-07,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"January 3, 2022",Anticipated,2022-01-03,"August 1, 2021",Actual,2021-08-01,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡b Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.","Active, not recruiting",NA,Phase 2,500,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:10:29Z,2021-12-02T04:10:29Z,103
NCT04880174,NA,2021-04-16,NA,NA,2021-05-05,2021-05-05,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"March 22, 2021",Actual,2021-03-22,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,Recruiting,NA,Not Applicable,800,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:35Z,2021-12-02T04:15:35Z,243
NCT04881227,NA,2021-05-10,NA,NA,2021-06-21,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Interventional,NA,NA,The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT),The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions,Recruiting,NA,Not Applicable,892,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:14:20Z,2021-12-02T04:14:20Z,196
NCT04873128,NA,2021-04-30,NA,NA,2021-06-10,2021-05-04,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-15,Actual,"June 10, 2021",Actual,2021-06-10,June 2021,2021-06-30,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,COVID 19-VAC,NA,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Recruiting,NA,Not Applicable,110,Anticipated,University Hospital Tuebingen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after analysis and unlimited.,NA,NA,Yes,The COVID19-VAC study will provide data in a pseudonymised manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts,2021-12-02T04:25:43Z,2021-12-02T04:25:43Z,207
NCT04871737,NA,2021-04-21,NA,NA,2021-05-26,2021-04-30,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 20, 2021",Actual,2021-05-20,May 2021,2021-05-31,June 2022,Anticipated,2022-06-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Study of a Live rNDV Based Vaccine Against COVID-19,"Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers",Recruiting,NA,Phase 1,90,Anticipated,"Laboratorio Avi-Mex, S.A. de C.V.",NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:24Z,2021-12-02T04:27:24Z,222
NCT04869592,NA,2021-04-24,NA,NA,2021-05-05,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,"October 25, 2022",Anticipated,2022-10-25,"October 25, 2022",Anticipated,2022-10-25,NA,Interventional,NA,NA,A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19,"Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older",Recruiting,NA,Phase 1/Phase 2,3580,Anticipated,"National Vaccine and Serum Institute, China",NA,15,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:29:31Z,2021-12-02T04:29:31Z,243
NCT04866069,NA,2021-04-26,NA,NA,2021-05-03,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,October 2021,Anticipated,2021-10-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,"Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.",Recruiting,NA,Phase 1,50,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:32:47Z,2021-12-02T04:32:47Z,245
NCT04863638,NA,2021-04-27,NA,NA,2021-05-11,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"April 29, 2021",Actual,2021-04-29,April 2021,2021-04-30,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,COVID-19,NA,"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated","A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged â‰¥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old",Recruiting,NA,Phase 4,4400,Anticipated,China National Biotec Group Company Limited,NA,18,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:34:54Z,2021-12-02T04:34:54Z,237
NCT04863131,NA,2021-04-15,NA,NA,2021-04-29,2021-04-23,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 28, 2021",Actual,2021-04-28,April 2021,2021-04-30,"January 31, 2023",Anticipated,2023-01-31,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,NA,NA,Safety and Immunogenicity of EXG-5003,Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,Fujita Health University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:35:17Z,2021-12-02T04:35:17Z,249
NCT04860739,NA,2021-04-22,NA,NA,2021-05-01,2021-04-22,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"April 24, 2021",Actual,2021-04-24,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"May 20, 2021",Anticipated,2021-05-20,NA,Interventional,CombiVacS,NA,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Immunogenicity Against SARS-Cov2 and Safety of Boosted Vaccination With COMIRNATY in Subjects Having Received Prime Vaccination With VAXZERIA","Active, not recruiting",NA,Phase 2,676,Actual,Spanish Clinical Research Network - SCReN,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within one year after study end,Published in EudraCT,NA,Yes,Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result.,2021-12-02T04:36:55Z,2021-12-02T04:36:55Z,247
NCT04860258,NA,2021-04-22,NA,NA,2021-10-01,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2021",Actual,2021-04-22,January 2021,2021-01-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:37:19Z,2021-12-02T04:37:19Z,94
NCT04844489,NA,2021-04-02,NA,NA,2021-06-15,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-21,Actual,"April 16, 2021",Actual,2021-04-16,June 2021,2021-06-30,"July 31, 2023",Anticipated,2023-07-31,"April 16, 2023",Anticipated,2023-04-16,NA,Interventional,COVIVAC-ID,NA,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,NA,Not Applicable,485,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:49:36Z,2021-12-02T04:49:36Z,202
NCT04844346,NA,2021-04-13,NA,NA,2021-04-16,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 19, 2021",Anticipated,2021-04-19,April 2021,2021-04-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,Plant Stanol Esters and COVID-19 Vaccination Response,The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine,Recruiting,NA,Not Applicable,100,Anticipated,Maastricht University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:49:46Z,2021-12-02T04:49:46Z,262
NCT04842708,NA,2020-12-29,NA,NA,2021-04-11,2021-04-11,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"December 24, 2020",Actual,2020-12-24,December 2020,2020-12-31,"October 24, 2021",Anticipated,2021-10-24,"October 24, 2021",Anticipated,2021-10-24,NA,Interventional,COVID-19,NA,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,NA,Not Applicable,50,Anticipated,Scentech Medical Technologies Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is not to be shared with other researchers.,2021-12-02T04:50:55Z,2021-12-02T04:50:55Z,267
NCT04840992,NA,2021-04-08,NA,NA,2021-07-27,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"April 20, 2021",Actual,2021-04-20,April 2021,2021-04-30,"July 15, 2022",Anticipated,2022-07-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,NA,NA,Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation,"A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older",Recruiting,NA,Phase 1/Phase 2,840,Anticipated,CanSino Biologics Inc.,NA,22,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:52:29Z,2021-12-02T04:52:29Z,160
NCT04839315,NA,2021-04-05,NA,NA,2021-04-07,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"February 15, 2021",Actual,2021-02-15,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,COVID-19 Vaccination in Rheumatic Disease Patients,Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases,Recruiting,NA,Early Phase 1,100,Anticipated,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:53:35Z,2021-12-02T04:53:35Z,271
NCT04838080,NA,2021-04-06,NA,NA,2021-04-10,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"October 20, 2021",Anticipated,2021-10-20,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,"Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,38,Anticipated,Kocak Farma,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:54:35Z,2021-12-02T04:54:35Z,268
NCT04834726,NA,2021-04-06,NA,NA,2021-08-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 29, 2021",Actual,2021-04-29,August 2021,2021-08-31,"July 6, 2021",Actual,2021-07-06,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,Not Applicable,19554,Actual,University of Pennsylvania,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:57:04Z,2021-12-02T04:57:04Z,126
NCT04833101,NA,2021-04-03,NA,NA,2021-08-04,2021-04-03,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"April 7, 2021",Actual,2021-04-07,June 2021,2021-06-30,"December 15, 2021",Anticipated,2021-12-15,"June 15, 2021",Actual,2021-06-15,NA,Interventional,NA,NA,Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population,"Active, not recruiting",NA,Phase 4,120,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:58:24Z,2021-12-02T04:58:24Z,152
NCT04830800,NA,2021-03-12,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"March 10, 2021",Actual,2021-03-10,April 2021,2021-04-30,"September 30, 2022",Anticipated,2022-09-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,NA,NA,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-75 Years in Vietnam",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,"Institute of Vaccines and Medical Biologicals, Vietnam",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There should be an agreement and approval by IRB before sharing IDP,2021-12-02T05:00:04Z,2021-12-02T05:00:04Z,277
NCT04824638,NA,2021-03-07,NA,NA,2021-08-02,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"March 8, 2021",Actual,2021-03-08,August 2021,2021-08-31,"October 30, 2023",Anticipated,2023-10-30,"June 29, 2021",Actual,2021-06-29,NA,Interventional,CoviCompareP,NA,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,"Active, not recruiting",NA,Phase 2,267,Actual,"ANRS, Emerging Infectious Diseases",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:05:42Z,2021-12-02T05:05:42Z,154
NCT04824391,NA,2021-03-25,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"February 10, 2021",Actual,2021-02-10,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.",Recruiting,NA,Phase 2,250,Anticipated,Health Institutes of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:06:25Z,2021-12-02T05:06:25Z,279
NCT04818281,NA,2021-03-24,NA,NA,2021-07-12,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"March 27, 2021",Actual,2021-03-27,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,"Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.",Recruiting,NA,Phase 1,36,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:11:39Z,2021-12-02T05:11:39Z,175
NCT04813796,NA,2021-03-22,NA,NA,2021-09-17,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-21,Actual,"March 11, 2021",Actual,2021-03-11,September 2021,2021-09-30,"April 13, 2022",Anticipated,2022-04-13,"April 13, 2022",Anticipated,2022-04-13,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years","Active, not recruiting",NA,Phase 1,106,Actual,"ModernaTX, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:15:18Z,2021-12-02T05:15:18Z,108
NCT04813770,NA,2021-03-23,NA,NA,2021-05-05,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 6, 2021",Actual,2021-04-06,May 2021,2021-05-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,Not Applicable,1113,Actual,University of Glasgow,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-12-02T05:15:30Z,2021-12-02T05:15:30Z,243
NCT04813562,NA,2021-03-19,NA,NA,2021-05-22,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"March 23, 2021",Actual,2021-03-23,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),"A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,480,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:15:48Z,2021-12-02T05:15:48Z,226
NCT04811664,NA,2021-03-19,NA,NA,2021-08-06,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"March 24, 2021",Actual,2021-03-24,August 2021,2021-08-31,"December 22, 2021",Anticipated,2021-12-22,"December 22, 2021",Anticipated,2021-12-22,NA,Interventional,CoVPN 3006,NA,A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine,"A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine",Recruiting,NA,Phase 3,37500,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:17:14Z,2021-12-02T05:17:14Z,150
NCT04805931,NA,2021-03-11,NA,NA,2021-06-25,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-25,2021-06-28,Actual,"March 15, 2021",Actual,2021-03-15,June 2021,2021-06-30,"November 1, 2021",Anticipated,2021-11-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,VEText,NA,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,COVID-19 Vaccine Rollout: VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,NA,Not Applicable,4311,Anticipated,VA Puget Sound Health Care System,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:39Z,2021-12-02T05:21:39Z,192
NCT04806113,NA,2021-03-12,NA,NA,2021-06-13,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-13,2021-06-15,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,"June 15, 2022",Anticipated,2022-06-15,"June 13, 2021",Actual,2021-06-13,NA,Interventional,COVIAAD,NA,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",NA,Phase 3,220,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:40Z,2021-12-02T05:21:40Z,204
NCT04805125,NA,2021-03-15,NA,NA,2021-06-14,2021-03-15,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"April 19, 2021",Actual,2021-04-19,June 2021,2021-06-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,COVERALL,NA,Immunocompromised Swiss Cohorts Based Trial Platform,Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform,"Active, not recruiting",NA,Phase 3,431,Actual,"University Hospital, Basel, Switzerland",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:22:25Z,2021-12-02T05:22:25Z,203
NCT04801888,NA,2021-03-15,NA,NA,2021-07-23,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,NA,NA,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:57Z,2021-12-02T05:24:57Z,164
NCT04801524,NA,2021-03-15,NA,NA,2021-03-22,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"February 7, 2021",Actual,2021-02-07,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Text-based Reminders to Promote COVID-19 Vaccinations,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,250000,Anticipated,"University of California, Los Angeles",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:25:23Z,2021-12-02T05:25:23Z,287
NCT04800965,NA,2021-02-06,NA,NA,2021-03-22,2021-03-14,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"January 31, 2021",Actual,2021-01-31,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Text-based Interventions to Promote COVID-19 Vaccinations,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,400000,Anticipated,"University of California, Los Angeles",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:25:42Z,2021-12-02T05:25:42Z,287
NCT04798677,NA,2021-03-12,NA,NA,2021-07-20,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"October 29, 2020",Actual,2020-10-29,March 2021,2021-03-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,"Efficacy and Tolerability of a Nutritional Supplementation With ABBC-1, a Symbiotic Combination of Beta-glucans and Selenium and Zinc Enriched Probiotics, in Volunteers Receiving the Influenza or the Covid-19 Vaccines",Recruiting,NA,Not Applicable,90,Anticipated,AB Biotek,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will be available upon request (blood analysis results and clinical assessment outcomes),2021-12-02T05:27:23Z,2021-12-02T05:27:23Z,167
NCT04798001,NA,2021-03-09,NA,NA,2021-07-01,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,"Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years",Recruiting,NA,Phase 1,130,Anticipated,"Meissa Vaccines, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:27:50Z,2021-12-02T05:27:50Z,186
NCT04794946,NA,2021-03-08,NA,NA,2021-06-18,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-23,Actual,"March 19, 2021",Actual,2021-03-19,March 2021,2021-03-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Interventional,NA,NA,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis","Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis - A Pilot Study",Recruiting,NA,Not Applicable,2200,Anticipated,"Institute of Liver and Biliary Sciences, India",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:30:11Z,2021-12-02T05:30:11Z,199
NCT04791423,NA,2021-02-22,NA,NA,2021-07-26,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-30,Actual,"March 15, 2021",Actual,2021-03-15,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,COVITAR,NA,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2/Phase 3,10300,Anticipated,ReiThera Srl,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:33:19Z,2021-12-02T05:33:19Z,161
NCT04789356,NA,2021-03-05,NA,NA,2021-07-22,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-26,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,"July 5, 2021",Actual,2021-07-05,NA,Interventional,COVACMANAUS,NA,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,"Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)","Active, not recruiting",NA,Phase 4,6233,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:35:26Z,2021-12-02T05:35:26Z,165
NCT04784767,NA,2021-03-03,NA,NA,2021-09-13,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 5, 2021",Actual,2021-04-05,September 2021,2021-09-30,"October 30, 2023",Anticipated,2023-10-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,NA,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.","Active, not recruiting",NA,Phase 1,29,Actual,U.S. Army Medical Research and Development Command,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:39:06Z,2021-12-02T05:39:06Z,112
NCT04783311,NA,2021-03-03,NA,NA,2021-04-23,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"February 23, 2021",Actual,2021-02-23,February 2021,2021-02-28,January 2023,Anticipated,2023-01-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,280,Anticipated,"EuBiologics Co.,Ltd",NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:40:20Z,2021-12-02T05:40:20Z,255
NCT04780659,NA,2021-02-19,NA,NA,2021-09-08,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"February 23, 2021",Actual,2021-02-23,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,COVAXID,NA,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),"Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study","Active, not recruiting",NA,Phase 4,540,Anticipated,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within one year after study end.,Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre),https://eudract.ema.europa.eu/index.html,Yes,"Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.",2021-12-02T05:42:16Z,2021-12-02T05:42:16Z,117
NCT04780035,NA,2021-02-25,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)","Active, not recruiting",NA,Phase 3,3000,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:42:48Z,2021-12-02T05:42:48Z,307
NCT04779827,NA,2021-02-21,NA,NA,2021-05-06,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"May 4, 2021",Actual,2021-05-04,May 2021,2021-05-31,"December 30, 2022",Anticipated,2022-12-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,NA,Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks,Improving Health Equity for COVID-19 Vaccination and Related Health Behaviors for At-risk Populations Using Online Social Networks,Recruiting,NA,Not Applicable,1920,Anticipated,University of Pennsylvania,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available when the primary intervention paper is published.,"Data will be shared as a part of the published paper, in forms of supplementary materials. The public can access the data through the publisher's website.",NA,Yes,We will share the data collected from our online experiments. All sets of data are anonymous.,2021-12-02T05:43:01Z,2021-12-02T05:43:01Z,242
NCT04775069,NA,2021-02-24,NA,NA,2021-05-21,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,"A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines",Recruiting,NA,Phase 4,900,Anticipated,Humanity & Health Medical Group Limited,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:46:45Z,2021-12-02T05:46:45Z,227
NCT04773665,NA,2021-02-24,NA,NA,2021-10-01,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"March 15, 2021",Actual,2021-03-15,October 2021,2021-10-31,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults",Recruiting,NA,Phase 1,141,Anticipated,VBI Vaccines Inc.,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:47:49Z,2021-12-02T05:47:49Z,94
NCT04771559,NA,2021-02-17,NA,NA,2021-08-01,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"July 1, 2021",Actual,2021-07-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,Not Applicable,1500,Actual,Bezmialem Vakif University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:19Z,2021-12-02T05:49:19Z,155
NCT04765839,NA,2021-02-02,NA,NA,2021-07-28,2021-02-19,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,CERC,NA,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations,Completed,NA,Not Applicable,74,Actual,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:53:35Z,2021-12-02T05:53:35Z,159
NCT04765436,NA,2021-02-16,NA,NA,2021-06-28,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"February 12, 2022",Anticipated,2022-02-12,"February 12, 2022",Anticipated,2022-02-12,NA,Interventional,NA,NA,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","Active, not recruiting",NA,Phase 1,60,Anticipated,Providence Therapeutics Holdings Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:54:00Z,2021-12-02T05:54:00Z,189
NCT04761822,NA,2021-02-17,NA,NA,2021-08-31,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"April 7, 2021",Actual,2021-04-07,August 2021,2021-08-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,SARS,NA,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Systemic Allergic Reactions to SARS-CoV-2 Vaccination,Recruiting,NA,Phase 2,3400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After completion of the trial, within 24 months status post database lock.","Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.

ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.",https://www.immport.org/home,Yes,Participant level data access and additional relevant materials will be made available upon completion of the trial.,2021-12-02T05:56:34Z,2021-12-02T05:56:34Z,125
NCT04760743,NA,2021-02-17,NA,NA,2021-02-17,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"December 17, 2020",Actual,2020-12-17,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years","Active, not recruiting",NA,Phase 1,50,Actual,"SK Chemicals Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:57:36Z,2021-12-02T05:57:36Z,320
NCT04760132,NA,2021-02-08,NA,NA,2021-02-23,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-26,Actual,"February 8, 2021",Actual,2021-02-08,February 2021,2021-02-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Interventional,ENFORCE,NA,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines,Recruiting,NA,Phase 4,10000,Anticipated,"Rigshospitalet, Denmark",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:58:28Z,2021-12-02T05:58:28Z,314
NCT04758273,NA,2021-02-09,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 7, 2020",Actual,2020-10-07,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial","Active, not recruiting",NA,Phase 1,180,Actual,"Beijing Minhai Biotechnology Co., Ltd",NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:00:01Z,2021-12-02T06:00:01Z,321
NCT04756830,NA,2021-02-15,NA,NA,2021-07-06,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"February 19, 2021",Actual,2021-02-19,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19,An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up,"Active, not recruiting",NA,Phase 4,1200,Actual,D'Or Institute for Research and Education,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:01:18Z,2021-12-02T06:01:18Z,181
NCT04756323,NA,2021-02-09,NA,NA,2021-02-16,2021-02-14,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 27, 2020",Actual,2020-10-27,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial","Active, not recruiting",NA,Phase 2,1000,Actual,"Beijing Minhai Biotechnology Co., Ltd",NA,12,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:01:24Z,2021-12-02T06:01:24Z,321
NCT04751682,NA,2021-02-08,NA,NA,2021-06-17,2021-02-11,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"November 30, 2021",Anticipated,2021-11-30,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,175,Anticipated,Bharat Biotech International Limited,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:05:41Z,2021-12-02T06:05:41Z,200
NCT04747821,NA,2021-02-05,NA,NA,2021-04-06,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"February 7, 2021",Actual,2021-02-07,April 2021,2021-04-30,February 2022,Anticipated,2022-02-28,May 2021,Anticipated,2021-05-31,NA,Interventional,Projeto S,NA,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac,"Active, not recruiting",NA,Phase 4,27711,Actual,Butantan Institute,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:08:56Z,2021-12-02T06:08:56Z,272
NCT04732819,NA,2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,Not Applicable,23768,Actual,Brown University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-12-02T06:21:40Z,2021-12-02T06:21:40Z,124
NCT04732468,NA,2021-01-27,NA,NA,2021-07-19,2021-01-28,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 24, 2021",Actual,2021-02-24,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,26,Actual,"ImmunityBio, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:21:55Z,2021-12-02T06:21:55Z,168
NCT04728594,NA,2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,Not Applicable,9566,Actual,Geisinger Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-12-02T06:24:45Z,2021-12-02T06:24:45Z,165
NCT04713488,NA,2021-01-13,NA,NA,2021-02-01,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"January 15, 2021",Actual,2021-01-15,January 2021,2021-01-31,"July 31, 2021",Anticipated,2021-07-31,"July 20, 2021",Anticipated,2021-07-20,NA,Interventional,NA,NA,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso","Active, not recruiting",NA,Phase 1/Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:38:00Z,2021-12-02T06:38:00Z,336
NCT04713553,NA,2021-01-15,NA,NA,2021-08-04,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,NA,Interventional,NA,NA,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T06:38:06Z,2021-12-02T06:38:06Z,152
NCT04710303,NA,2021-01-13,NA,NA,2021-03-09,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"March 2, 2021",Actual,2021-03-02,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)",Recruiting,NA,Phase 1,35,Anticipated,"ImmunityBio, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:40:43Z,2021-12-02T06:40:43Z,300
NCT04706403,NA,2021-01-05,NA,NA,2021-07-26,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-08-02,Actual,"January 12, 2021",Actual,2021-01-12,July 2021,2021-07-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,Not Applicable,1706,Actual,"University of Massachusetts, Worcester",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:43:34Z,2021-12-02T06:43:34Z,161
NCT04691947,NA,2020-11-14,NA,NA,2020-12-31,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"November 5, 2020",Actual,2020-11-05,December 2020,2020-12-31,"March 15, 2022",Anticipated,2022-03-15,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,ERUCOV-VAC,NA,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,44,Anticipated,Health Institutes of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:56:33Z,2021-12-02T06:56:33Z,368
NCT04691908,NA,2020-12-21,NA,NA,2021-07-23,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"December 25, 2020",Actual,2020-12-25,December 2020,2020-12-31,"July 11, 2021",Actual,2021-07-11,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:56:25Z,2021-12-02T06:56:25Z,164
NCT04685603,NA,2020-12-22,NA,NA,2020-12-24,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-29,Actual,"December 7, 2020",Actual,2020-12-07,December 2020,2020-12-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,NA,Dendritic Cell Vaccine to Prevent COVID-19,"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Recruiting,NA,Phase 1,27,Anticipated,Indonesia-MoH,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:02:50Z,2021-12-02T07:02:50Z,375
NCT04679909,NA,2020-12-21,NA,NA,2021-07-14,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-15,Actual,"February 25, 2021",Actual,2021-02-25,July 2021,2021-07-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),"A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses","Active, not recruiting",NA,Phase 1,92,Actual,"Altimmune, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:08:19Z,2021-12-02T07:08:19Z,173
NCT04674189,NA,2020-12-14,NA,NA,2021-07-20,2020-12-14,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,"July 12, 2022",Anticipated,2022-07-12,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)","Active, not recruiting",NA,Phase 3,2360,Actual,CureVac AG,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:14:04Z,2021-12-02T07:14:04Z,167
NCT04673149,NA,2020-12-11,NA,NA,2020-12-23,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"December 23, 2020",Actual,2020-12-23,December 2020,2020-12-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,NA,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,345,Anticipated,"GeneOne Life Science, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:15:10Z,2021-12-02T07:15:10Z,376
NCT04672291,NA,2020-10-05,NA,NA,2021-08-17,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"July 21, 2021",Actual,2021-07-21,February 2021,2021-02-28,"January 31, 2023",Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults,"A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults",Recruiting,NA,Phase 1,43,Anticipated,"Oncovir, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:15:55Z,2021-12-02T07:15:55Z,139
NCT04668339,NA,2020-11-25,NA,NA,2021-03-26,2020-12-10,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"January 7, 2021",Actual,2021-01-07,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants","Active, not recruiting",NA,Phase 2,600,Anticipated,"Arcturus Therapeutics, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-12-02T07:19:03Z,2021-12-02T07:19:03Z,283
NCT04666012,NA,2020-12-10,NA,NA,2021-07-26,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 29, 2020",Actual,2020-12-29,July 2021,2021-07-31,April 2022,Anticipated,2022-04-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,150,Actual,"Cellid Co., Ltd.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:21:10Z,2021-12-02T07:21:10Z,161
NCT04659941,NA,2020-12-08,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"October 1, 2022",Anticipated,2022-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ProBCG,NA,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,NA,Phase 2,1000,Anticipated,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:26:18Z,2021-12-02T07:26:18Z,391
NCT04659239,NA,2020-12-05,NA,NA,2021-02-09,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"January 28, 2021",Actual,2021-01-28,February 2021,2021-02-28,July 2022,Anticipated,2022-07-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above",Enrolling by invitation,NA,Phase 3,34020,Anticipated,Chinese Academy of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:27:00Z,2021-12-02T07:27:00Z,328
NCT04655625,NA,2020-11-26,NA,NA,2021-04-05,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"November 23, 2020",Actual,2020-11-23,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"April 2, 2021",Actual,2021-04-02,NA,Interventional,NA,NA,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults","Active, not recruiting",NA,Phase 2/Phase 3,500,Actual,"AnGes, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:29:48Z,2021-12-02T07:29:48Z,273
NCT04651790,NA,2020-11-20,NA,NA,2021-02-25,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"November 27, 2020",Actual,2020-11-27,February 2021,2021-02-28,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CoronaVac3CL,NA,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.",Recruiting,NA,Phase 3,2300,Anticipated,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:33:28Z,2021-12-02T07:33:28Z,312
NCT04652102,NA,2020-12-01,NA,NA,2021-07-21,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"December 14, 2020",Actual,2020-12-14,October 2020,2020-10-31,"May 15, 2022",Anticipated,2022-05-15,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,NA,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","Active, not recruiting",NA,Phase 2/Phase 3,39693,Actual,CureVac AG,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:33:04Z,2021-12-02T07:33:04Z,166
NCT04649151,NA,2020-11-30,NA,NA,2021-08-19,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"December 9, 2020",Actual,2020-12-09,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,TeenCove,NA,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age","Active, not recruiting",NA,Phase 2/Phase 3,3732,Actual,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:35:21Z,2021-12-02T07:35:21Z,137
NCT04649021,NA,2020-11-17,NA,NA,2021-02-12,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"December 4, 2020",Actual,2020-12-04,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study","Active, not recruiting",NA,Phase 2,950,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:35:43Z,2021-12-02T07:35:43Z,325
NCT04648800,NA,2020-10-18,NA,NA,2020-11-30,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"July 7, 2020",Actual,2020-07-07,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,"A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland",Recruiting,NA,Phase 3,1000,Anticipated,University of Rzeszow,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:35:33Z,2021-12-02T07:35:33Z,399
NCT04646590,NA,2020-11-25,NA,NA,2021-05-06,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"December 16, 2020",Actual,2020-12-16,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,"A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19",Recruiting,NA,Phase 3,29000,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:37:40Z,2021-12-02T07:37:40Z,242
NCT04641481,NA,2020-11-09,NA,NA,2021-03-18,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"November 16, 2020",Actual,2020-11-16,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,NA,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adultsâ‰¥18 Yrs of Age","Active, not recruiting",NA,Phase 3,25800,Actual,Bharat Biotech International Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:42:10Z,2021-12-02T07:42:10Z,291
NCT04640402,NA,2020-11-19,NA,NA,2021-03-28,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-03-30,Actual,"November 17, 2020",Actual,2020-11-17,November 2020,2020-11-30,"November 18, 2021",Anticipated,2021-11-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,NA,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,960,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,16,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:43:17Z,2021-12-02T07:43:17Z,281
NCT04640233,NA,2020-11-17,NA,NA,2021-05-31,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"November 30, 2020",Actual,2020-11-30,May 2021,2021-05-31,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Ð¡ov-2 Infection in Indian Healthy Subjects","Active, not recruiting",NA,Phase 2/Phase 3,1600,Actual,Dr. Reddy's Laboratories Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:43:03Z,2021-12-02T07:43:03Z,217
NCT04639375,NA,2020-11-16,NA,NA,2021-08-23,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"June 12, 2022",Anticipated,2022-06-12,"June 12, 2021",Actual,2021-06-12,NA,Interventional,NA,NA,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2),"Active, not recruiting",NA,Phase 4,300,Actual,E-MO Biology Inc,NA,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:43:52Z,2021-12-02T07:43:52Z,133
NCT04636697,NA,2020-11-12,NA,NA,2021-09-07,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"November 19, 2020",Actual,2020-11-19,June 2021,2021-06-30,"April 30, 2022",Anticipated,2022-04-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older","Active, not recruiting",NA,Phase 2/Phase 3,30918,Anticipated,Medicago,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:08Z,2021-12-02T07:46:08Z,118
NCT04636333,NA,2020-11-17,NA,NA,2021-05-22,2020-11-17,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"October 30, 2020",Actual,2020-10-30,May 2021,2021-05-31,"January 7, 2022",Anticipated,2022-01-07,"December 7, 2021",Anticipated,2021-12-07,NA,Interventional,NA,NA,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study,Recruiting,NA,Phase 1,216,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:33Z,2021-12-02T07:46:33Z,226
NCT04627675,NA,2020-11-06,NA,NA,2021-06-02,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"December 30, 2020",Actual,2020-12-30,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,July 2021,Anticipated,2021-07-31,NA,Interventional,CORVax12,NA,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response","Active, not recruiting",NA,Phase 1,36,Anticipated,Providence Health & Services,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:53:49Z,2021-12-02T07:53:49Z,215
NCT04619628,NA,2020-11-05,NA,NA,2021-07-26,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 11, 2020",Actual,2020-12-11,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,"June 26, 2021",Actual,2021-06-26,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19","Active, not recruiting",NA,Phase 1,48,Anticipated,"Codagenix, Inc",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:00:00Z,2021-12-02T08:00:00Z,161
NCT04617483,NA,2020-11-04,NA,NA,2021-07-26,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Actual,2021-05-31,"November 28, 2020",Actual,2020-11-28,NA,Interventional,NA,NA,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:04:10Z,2021-12-02T08:04:10Z,161
NCT04612972,NA,2020-08-18,NA,NA,2021-04-27,2020-10-29,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 9, 2020",Actual,2020-09-09,April 2021,2021-04-30,"December 19, 2021",Anticipated,2021-12-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,Covid-Peru,NA,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Ensayo ClÃ­nico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la PoblaciÃ³n Sana de 18 aÃ±os o mÃ¡s, en PerÃº","Active, not recruiting",NA,Phase 3,12000,Actual,Universidad Peruana Cayetano Heredia,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:08:40Z,2021-12-02T08:08:40Z,251
NCT04611802,NA,2020-10-30,NA,NA,2021-11-18,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-12-01,Estimate,"December 27, 2020",Actual,2020-12-27,November 2021,2021-11-30,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)","Active, not recruiting",NA,Phase 3,33000,Anticipated,Novavax,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:09:49Z,2021-12-02T08:09:49Z,46
NCT04608305,NA,2020-10-26,NA,NA,2021-04-25,2020-10-27,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-25,2021-04-27,Actual,"October 28, 2020",Actual,2020-10-28,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults",Recruiting,NA,Phase 1/Phase 2,1040,Anticipated,Israel Institute for Biological Research (IIBR),NA,18,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:12:31Z,2021-12-02T08:12:31Z,253
NCT04604743,NA,2020-10-25,NA,NA,2021-05-21,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"April 20, 2021",Actual,2021-04-20,May 2021,2021-05-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Interventional,NA,NA,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Exploratory Sequential Mixed Methods Cluster Randomized Controlled Implementation Science Trial to Develop a Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for African American Older Adolescents in Rural Alabama,Recruiting,NA,Not Applicable,4,Anticipated,University of Alabama at Birmingham,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data sharing with occur in compliance with Merck's data sharing policy.,2021-12-02T08:15:38Z,2021-12-02T08:15:38Z,227
NCT04591717,NA,2020-10-13,NA,NA,2021-07-19,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"October 19, 2020",Actual,2020-10-19,October 2020,2020-10-31,"November 19, 2021",Anticipated,2021-11-19,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,34,Actual,"ImmunityBio, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:25:48Z,2021-12-02T08:25:48Z,168
NCT04591184,NA,2020-09-23,NA,NA,2021-09-07,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-14,Actual,"April 7, 2021",Actual,2021-04-07,September 2021,2021-09-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,"Phase I/II Trial to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS CoV-2 [Covigenix VAX-001] in Healthy Adults 18 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,36,Anticipated,Entos Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:26:23Z,2021-12-02T08:26:23Z,118
NCT04587219,NA,2020-10-13,NA,NA,2021-01-20,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years","Active, not recruiting",NA,Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:29:13Z,2021-12-02T08:29:13Z,348
NCT04582344,NA,2020-10-01,NA,NA,2021-07-26,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"September 14, 2020",Actual,2020-09-14,February 2021,2021-02-28,"April 15, 2022",Anticipated,2022-04-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NA,NA,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated","Active, not recruiting",NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:32:54Z,2021-12-02T08:32:54Z,161
NCT04568811,NA,2020-09-28,NA,NA,2021-02-08,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"September 26, 2020",Actual,2020-09-26,September 2020,2020-09-30,"September 27, 2021",Anticipated,2021-09-27,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:46Z,2021-12-02T08:43:46Z,329
NCT04566770,NA,2020-09-22,NA,NA,2020-11-25,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 24, 2020",Actual,2020-09-24,September 2020,2020-09-30,"October 20, 2022",Anticipated,2022-10-20,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,NA,NA,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV",Recruiting,NA,Phase 2,481,Anticipated,CanSino Biologics Inc.,NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:45:12Z,2021-12-02T08:45:12Z,404
NCT04563702,NA,2020-09-21,NA,NA,2021-04-05,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"September 21, 2020",Actual,2020-09-21,April 2021,2021-04-30,October 2021,Anticipated,2021-10-31,"May 10, 2021",Anticipated,2021-05-10,NA,Interventional,NA,NA,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1,35,Actual,Vaxart,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2021-12-02T08:47:23Z,2021-12-02T08:47:23Z,273
NCT04564716,NA,2020-09-24,NA,NA,2020-12-01,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"April 10, 2021",Anticipated,2021-04-10,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus","Active, not recruiting",NA,Phase 3,100,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:46:50Z,2021-12-02T08:46:50Z,398
NCT04560881,NA,2020-09-16,NA,NA,2020-11-25,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 16, 2020",Actual,2020-09-16,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years","Active, not recruiting",NA,Phase 3,3000,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:49:34Z,2021-12-02T08:49:34Z,404
NCT04552366,NA,2020-09-15,NA,NA,2020-12-03,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-07,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,"Active, not recruiting",NA,Phase 1,149,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:56:20Z,2021-12-02T08:56:20Z,396
NCT04551547,NA,2020-09-15,NA,NA,2021-07-26,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years",Enrolling by invitation,NA,Phase 1/Phase 2,552,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:57:08Z,2021-12-02T08:57:08Z,161
NCT04550351,NA,2020-08-16,NA,NA,2021-01-26,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:57:31Z,2021-12-02T08:57:31Z,342
NCT04546841,NA,2020-08-26,NA,NA,2021-09-07,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 27, 2020",Actual,2020-11-27,August 2021,2021-08-31,"December 20, 2021",Anticipated,2021-12-20,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,pVAC,NA,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,"Active, not recruiting",NA,Phase 1,36,Anticipated,University Hospital Tuebingen,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:00:14Z,2021-12-02T09:00:14Z,118
NCT04545749,NA,2020-09-02,NA,NA,2021-06-04,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"September 25, 2020",Actual,2020-09-25,June 2021,2021-06-30,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:01:16Z,2021-12-02T09:01:16Z,213
NCT04542330,NA,2020-09-07,NA,NA,2020-11-22,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-22,2020-11-24,Actual,"September 15, 2020",Actual,2020-09-15,November 2020,2020-11-30,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.,Recruiting,NA,Phase 3,1900,Anticipated,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Per justified request on email (cbenn@health.sdu.dk),NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-12-02T09:03:47Z,2021-12-02T09:03:47Z,407
NCT04542395,NA,2020-09-03,NA,NA,2021-07-27,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"June 1, 2021",Actual,2021-06-01,September 2020,2020-09-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2022",Anticipated,2022-11-30,NA,Interventional,NA,NA,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents,Recruiting,NA,Not Applicable,310,Anticipated,Charles Drew University of Medicine and Science,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:03:42Z,2021-12-02T09:03:42Z,160
NCT04540419,NA,2020-08-17,NA,NA,2021-07-19,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"September 11, 2020",Actual,2020-09-11,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"June 19, 2021",Actual,2021-06-19,NA,Interventional,NA,NA,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers","Active, not recruiting",NA,Phase 3,500,Actual,NPO Petrovax,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:05:05Z,2021-12-02T09:05:05Z,168
NCT04540185,NA,2020-09-04,NA,NA,2020-09-05,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-05,2020-09-09,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,OPV-NA831,NA,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2021-12-02T09:05:42Z,2021-12-02T09:05:42Z,485
NCT04537949,NA,2020-09-02,NA,NA,2021-06-23,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-25,Actual,"September 9, 2020",Actual,2020-09-09,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,96,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:07:07Z,2021-12-02T09:07:07Z,194
NCT04537663,NA,2020-08-28,NA,NA,2021-05-18,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-21,Actual,"August 25, 2020",Actual,2020-08-25,May 2021,2021-05-31,"July 25, 2021",Anticipated,2021-07-25,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,BCG-PRIME,NA,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Bacillus Calmette-GuÃ©rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial,Recruiting,NA,Phase 4,5200,Anticipated,UMC Utrecht,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:07:29Z,2021-12-02T09:07:29Z,230
NCT04536051,NA,2020-09-01,NA,NA,2020-11-23,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,10300,Anticipated,University of Oxford,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:08:39Z,2021-12-02T09:08:39Z,406
NCT04533399,NA,2020-08-28,NA,NA,2020-10-30,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-02,Actual,"August 17, 2020",Actual,2020-08-17,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,4400,Anticipated,Novavax,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:10:43Z,2021-12-02T09:10:43Z,430
NCT04530656,NA,2020-08-27,NA,NA,2021-02-08,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"August 28, 2020",Actual,2020-08-28,August 2020,2020-08-31,"August 28, 2021",Anticipated,2021-08-28,"October 28, 2020",Actual,2020-10-28,NA,Interventional,NA,NA,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study","Active, not recruiting",NA,Phase 1,168,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:13:01Z,2021-12-02T09:13:01Z,329
NCT04530396,NA,2020-08-25,NA,NA,2021-01-20,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"September 7, 2020",Actual,2020-09-07,August 2020,2020-08-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,RESIST,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment","Active, not recruiting",NA,Phase 3,33758,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:51Z,2021-12-02T09:12:51Z,348
NCT04530357,NA,2020-08-26,NA,NA,2021-05-01,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"September 19, 2020",Actual,2020-09-19,February 2021,2021-02-28,"April 25, 2021",Actual,2021-04-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:13:10Z,2021-12-02T09:13:10Z,247
NCT04528641,NA,2020-08-19,NA,NA,2021-07-09,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,NA,Interventional,NA,NA,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:14:13Z,2021-12-02T09:14:13Z,178
NCT04527575,NA,2020-08-11,NA,NA,2021-02-20,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,EpiVacCorona,NA,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:15:11Z,2021-12-02T09:15:11Z,317
NCT05107479,NA,2021-10-11,NA,NA,2021-11-18,2021-11-02,2021-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-12-01,Estimate,"November 9, 2021",Actual,2021-11-09,November 2021,2021-11-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo,Effectiveness of Interactive Voice Response (IVR) for COVID-19 Vaccination Training of Frontline Health Workers: Experimental Evidence From the Democratic Republic of the Congo,"Active, not recruiting",NA,Not Applicable,8959,Anticipated,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:28:11Z,2021-12-02T09:28:11Z,46
NCT04516746,NA,2020-08-17,NA,NA,2021-11-19,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-12-01,Estimate,"August 28, 2020",Actual,2020-08-28,November 2021,2021-11-30,"February 14, 2023",Anticipated,2023-02-14,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 3,32459,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-02T09:34:20Z,2021-12-02T09:34:20Z,45
NCT05142514,NA,2021-11-17,NA,NA,2021-12-01,2021-12-01,2021-12-02,Estimate,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-02,Estimate,"November 11, 2021",Actual,2021-11-11,December 2021,2021-12-31,"June 27, 2022",Anticipated,2022-06-27,"December 27, 2021",Anticipated,2021-12-27,NA,Interventional,NA,NA,"Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)","A Phase IIb Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Candidate Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Adult Healthy Volunteers",Recruiting,NA,Phase 2,256,Anticipated,"Hipra Scientific, S.L.U",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:51:57Z,2021-12-03T11:51:57Z,33
NCT05142488,NA,2021-11-30,NA,NA,2021-12-01,2021-12-01,2021-12-02,Estimate,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-02,Estimate,"November 9, 2021",Actual,2021-11-09,December 2021,2021-12-31,"March 30, 2023",Anticipated,2023-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,NA,NA,Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine,"Study of Immunogenicity Equivalence After a Homologous Third Dose of Covid-19 (Recombinante) Vaccine, 6 Months After the Second Dose, Comparing Intervals of 8 and 12 Weeks Between the First Two Doses.",Recruiting,NA,Phase 4,662,Anticipated,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T11:51:58Z,2021-12-03T11:51:58Z,33
NCT05142319,NA,2021-11-30,NA,NA,2021-11-30,2021-11-30,2021-12-02,Estimate,NA,NA,NA,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"October 12, 2021",Actual,2021-10-12,November 2021,2021-11-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,PRIBIVAC,NA,Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC],Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19,Recruiting,NA,Phase 3,600,Anticipated,Tan Tock Seng Hospital,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,All study findings and documents will be regarded as confidential. The investigators and other study personnel must not disclose such information without prior written approval from the PI. Participant confidentiality will be strictly maintained to the extent possible under the law and local hospital policy. Identifiable information will be removed from any published data.,2021-12-03T11:52:09Z,2021-12-03T11:52:09Z,34
NCT05142553,NA,2021-11-17,NA,NA,2021-12-01,2021-12-01,2021-12-02,Estimate,NA,NA,NA,NA,NA,NA,2021-12-01,2021-12-02,Estimate,"November 16, 2021",Actual,2021-11-16,December 2021,2021-12-31,"November 30, 2022",Anticipated,2022-11-30,"January 7, 2022",Anticipated,2022-01-07,NA,Interventional,NA,NA,"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Healthy Adults Volunteers Fully Vaccinated","A Phase IIb, Double-blind, Randomised, Active-controlled, Multi-centre, Non-inferiority Trial Followed by a Phase III, Single-arm, Open-label Trial, to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)SARS-CoV-2, in Adults Fully Vaccinated Against COVID-19",Recruiting,NA,Phase 2,1075,Anticipated,"Hipra Scientific, S.L.U",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:51:56Z,2021-12-03T11:51:56Z,33
NCT04526990,NA,2020-08-22,NA,NA,2021-01-21,2020-08-22,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"September 15, 2020",Actual,2020-09-15,December 2020,2020-12-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase â…¢ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,40000,Anticipated,CanSino Biologics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:18Z,2021-10-12T06:56:18Z,347
NCT04527081,NA,2020-08-24,NA,NA,2021-10-01,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"August 31, 2020",Actual,2020-08-31,October 2021,2021-10-31,"September 24, 2021",Actual,2021-09-24,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:20Z,2021-10-12T06:56:20Z,94
NCT04510207,NA,2020-08-03,NA,NA,2021-04-02,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"July 16, 2020",Actual,2020-07-16,April 2021,2021-04-30,"September 16, 2021",Anticipated,2021-09-16,"June 16, 2021",Anticipated,2021-06-16,NA,Interventional,COVID-19,NA,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:26Z,2021-10-12T06:58:26Z,276
